

June 28th - July 1st 2023
Alpbach, Tyrol

www.epc2023.eu



55th

EPC meeting

in cooperation with the JPS

Scientific Program



UNITED EUROPEAN
GASTROENTEROLOGY

ueg week

United European Gastroenterology Week Copenhagen

UEG wishes you
a successful
55th Meeting of
the European
Pancreatic Club!

Bella Center and Online

October 14–17, 2023

Meet. Exchange. Evolve
ueg.eu/week

Table of Contents

Welcome	4
Organising Committees.....	5
Floor Plan	6
Program Overview	8
Program	12
Wednesday, June 28th 2023	12
Thursday, June 29th 2023	16
Friday, June 30th 2023	22
Saturday, July 1st 2023	27
Satellite Meetings.....	30
Non-Commercial Sponsors	32
Posters.....	33
Commercial Part	60
Sponsors	61
Symposia	62
General Information.....	66
Social Program	69

Welcome to EPC 2023



Dear Colleagues,

We look forward to welcoming you to the 55th Annual Meeting of the European Pancreatic Club in beautiful Alpbach in Tyrol. Alpbach is located at 1,000 m altitude near the Northern main alpine ridge on a sunny plateau at the foot of the Gratslspitz. It was voted "Austria's most beautiful village" with its uniform and rustic wooden building style. In addition to a romantic alpine idyll, it captivates with a very modern and large international congress center that combines modernity and tradition in its architecture.



Heiko Witt
EPC President

Due to the political decisions related to COVID-19 and the war in Ukraine, this is the first face-to-face meeting in 4 years. So we are happy that we can get together again after such a long time to exchange ideas and maybe also to drink a beer or two in friendship.

The event is organised for the first time jointly with the Japan Pancreas Society (JPS) and in cooperation with the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). The local organisation teams from Europe and Japan have put together a broad and attractive program. The aim was in particular to win young talents for lectures and thus to offer the next generation an appropriate forum. The congress is preceded by an extensive postgraduate course, which is aimed in particular at young colleagues, but also offers attractive lectures for experienced pancreatologists. The course was planned together with ESPGHAN and focuses on hereditary paediatric diseases of the exocrine pancreas from hereditary pancreatitis to cystic fibrosis and rare syndromes. We are pleased to have won internationally renowned speakers from three continents for this course. I would like to thank the EPC Council and program committees for their support in planning the sessions, as well as the invited speakers and abstract presenters who share their knowledge with us.

An EPC meeting of this magnitude would not have been possible without the generous support of our industry sponsors. Our thanks go to all sponsors, exhibitors and other supporters.

Since the Annual Meeting is not only intended for scientific and professional exchange during the sessions, we have tried to create space for personal discussions with attractive social events. Especially the society dinner, which takes you to the Hornboden at 1827 m above sea level, offers the right cosy atmosphere.

Organising Committees



Heiko Witt
Munich, EPC President

Hana Algül
Munich

Ekin Demir
Munich

Maren Ewers
Munich

Helmut Friess
Munich

Robert Grützmann
Erlangen

Matthias Hebrok
Munich

Sebastian Krug
Halle

Julia Mayerle
Munich

Alexander Meining
Würzburg

Christian Pilarsky
Erlangen

Maximilian Reichert
Munich

Jonas Rosendahl
Halle



Yoshifumi Takeyama
Osaka, JPS President

Takao Itoi
Tokyo

Atsushi Masamune
Sendai

Takuji Okusaka
Tokyo

Sohei Sato
Osaka

Kyoichi Takaori
Kyoto

Kazushige Uchida
Kōchi

Michiaki Unno
Sendai




Frank Bodewes
Groningen


Etna Masip
Valencia

Isabelle Scheers
Brussels

Michael Wilschanski
Jerusalem

Floor Plan (Ground floor)





Program Overview

Wednesday, June 28th 2023

TIME	EVENT	VENUE
09:00-10:30	YOUPIIE session	Herz-Kremenak
10:30-10:55	Coffee break	Congress Center
10:55-18:55	EPC ESPGHAN Postgraduate Course: Inherited Diseases of the Exocrine Pancreas	Herz-Kremenak
10:55-12:15	Pancreas development & transcription factors	Herz-Kremenak
12:15-13:15	Satellite Symposium	Herz-Kremenak
13:15-14:00	Lunch	Congress Center
14:00-16:00	Of Mice and Men: genetics & animal models of CP	Herz-Kremenak
16:00-16:20	Coffee break	Congress Center
16:20-17:30	Cystic fibrosis	Herz-Kremenak
17:30-18:05	Peter Durie Memorial Lecture	Herz-Kremenak
18:05-18:55	Rare inherited diseases	Herz-Kremenak
19:00-21:00	Welcome reception with Tyrolean snacks	Congress Center

Program Overview

Thursday, June 29th 2023

TIME	EVENT	VENUE
07:00-08:00	Pancreatology Editorial Board Meeting	von Hayek
07:00-08:00	YOUPIIE Breakfast	Liechtenstein
08:00-08:05	Welcome and Opening of the EPC	Herz-Kremenak
08:05-08:50	Chronic Pancreatitis	Herz-Kremenak
08:50-10:10	Pancreatic cancer	Herz-Kremenak
10:10-10:25	Coffee break	Congress Center
10:25-12:30	Autoimmune pancreatitis (JPS-EPC)	Herz-Kremenak
12:30-14:30	Lunch & Poster Walk	Congress Center
12:30-14:30	Global guidelines on the management and treatment of pancreatic cystic neoplasms	von Hayek
12:45-13:45	Satellite Symposium	Herz-Kremenak
14:30-15:20	Awards Session	Herz-Kremenak
15:20-16:00	Endoscopy	Herz-Kremenak
16:00-16:20	Coffee break	Congress Center
16:20-16:50	Satellite Symposium	Herz-Kremenak
16:50-17:40	Pancreatic cancer	Herz-Kremenak
17:40-18:30	Cystic pancreatic lesions	Herz-Kremenak
18:30-19:30	YOUPIIE & HPSG joint Reception (by invitation only)	Otto-Molden-Foyer
19:30-22:30	Faculty Dinner (by invitation only)	

Program Overview

Friday, June 30th 2023

TIME	EVENT	VENUE
07:00-08:30	EPC Council Meeting	Liechtenstein
07:30-08:40	Acute & autoimmune pancreatitis	Herz-Kremenak
08:40-09:10	Pancreatic cancer	Herz-Kremenak
09:10-10:10	Pancreas 2000	Herz-Kremenak
10:10-10:25	Coffee break	Congress Center
10:25-12:30	Pancreatic cancer (JPS-EPC)	Herz-Kremenak
12:30-14:30	Lunch & Poster Walk	Congress Center
12:30-13:30	Satellite Symposium	Herz-Kremenak
12:35-13:55	ESPAC breakout meeting EPC 2023	Liechtenstein
13:30-14:25	COST project workshop	von Hayek
14:30-15:40	Awards Session	Herz-Kremenak
15:40-16:20	Studies	Herz-Kremenak
16:20-16:40	Coffee break	Congress Center
16:40-17:25	Pancreatic cancer	Herz-Kremenak
16:30-17:30	UEG EPI Guidelines Meeting	Liechtenstein
17:30-19:00	EPC General Assembly (members only)	Herz-Kremenak
19:30-23:30	EPC Evening	Hornboden

Program Overview

Saturday, July 1st 2023

TIME	EVENT	VENUE
07:30-08:30	Acute Pancreatitis Interest Group	Liechtenstein
08:30-09:50	Pancreatic cancer	Herz-Kremenak
10:00-10:50	Pancreatitis	Herz-Kremenak
10:50-11:10	Coffee break	Congress Center
11:10-12:30	Neuroendocrine & pancreatic cancer	Herz-Kremenak
12:30-13:20	Fatty pancreas & pancreatitis	Herz-Kremenak
13:20-13:40	Closing session	Herz-Kremenak
13:35-14:15	Lunch	Congress Center

Program

Wednesday, June 28th 2023

09:00-10:30 YOUPIIE session

Chair: Giovanni Marchegiani (Padova, Italy),
Hanna Sternby (Uppsala, Sweden)

09:00-09:05 Introduction

Hanna Sternby (Uppsala, Sweden)

09:05-09:20 How do I inspire young colleagues to do research?

Julia Mayerle (Munich, Germany)

09:20-09:30 YOUPIIE basic science: biomarkers for pancreatic cancer screening

Iris J M Levink (Rotterdam, Netherlands)

09:30-09:40 YOUPIIE clinical: insight into pancreatic cancer risk – protective factors

Livia Archibugi (Milan, Italy)

09:40-09:50 YOUPIIE surgery: the future of PDAC surgery

Ville Sallinen (Helsinki, Finland)

09:50-10:00 What's HOT in 2023: New Guidelines on IPMN – It is time for surveillance discontinuation?

Giovanni Marchegiani (Padova, Italy)

10:00-10:10 What's HOT in 2023: The IAP New Guidelines on IPMN

Kyoichi Takaori (Kyoto, Japan)

10:10-10:30 Youppie round table debate: Hands-on management of pancreatic cystic neoplasms

Case report

Tommaso Dall'Olio (Verona, Italy)

The endoscopist view

Daniel de la Iglesia Garcia (Santiago de Compostela, Spain)

The surgeon view

Hanna Sternby (Uppsala, Sweden)

10:30-10:55 Coffee break

Wednesday, June 28th 2023

10:55-18:55 EPC ESPGHAN Postgraduate Course: Inherited Diseases of the Exocrine Pancreas

Course directors:

Matthias Hebrok (Munich, Germany)

Isabelle Scheers (Brussels, Belgium) 

Heiko Witt (Munich, Germany)  

in association with

ueg

United European Gastroenterology (UEG) is Europe's home and umbrella for multidisciplinary gastroenterology and unites over 50,000 engaged professionals from national and specialist societies, individual digestive health experts, and related scientists from all fields and career stages.

10:55-12:15 Pancreas development & transcription factors

Chair: Matthias Hebrok (Munich, Germany),
Maximilian Reichert (Munich, Germany)

10:55-11:20 Deconstructing the liver and pancreas lineages: many paths and plenty of plasticity

Francesca Spagnoli (London, UK)

11:20-11:30 O-01: Single-cell profiling of GP2-enriched pancreatic progenitors to simultaneously create acinar, ductal and endocrine organoids

Sarah Merz (Ulm, Germany)

11:30-11:55 Pancreatic transcription factors: from development to disease

Francisco X. Real (Madrid, Spain)

11:55-12:05 O-02: GATA6 functions at distal enhancer regions to control classical pancreatic ductal carcinoma identity by promoting promoter-proximal pause release

Thomas Ekstrom (Stuttgart, Germany)

12:05-12:15 O-03: HNF1A plays a context-dependent role in pancreatic cancer initiation and progression

Irene Felipe (Madrid, Spain)

12:15-13:15 Satellite Symposium (see page 62)

13:15-14:00 Lunch

Program

Wednesday, June 28th 2023

14:00-16:00 Of Mice and Men: genetics & animal models of CP

Chair: Jonas Rosendahl (Halle, Germany), Anders Molven (Bergen, Norway)

14:00-14:25 The current gang of bad boys

Atsushi Masamune (Sendai, Japan)

14:25-14:35 O-04: Chronic pancreatitis in children – report of 484 cases

Grzegorz Oracz (Warsaw, Poland)

14:35-14:45 O-05: Carboxyl ester lipase (CEL) in pancreatic disease: pathogenicity of CEL-MODY, but not CEL-HYB1, depends on cysteine residues in the hypervariable tail region

Karianne Fjeld (Bergen, Norway)

14:45-15:10 Let's make the rodent sick!

Miklós Sahin-Tóth (Los Angeles, USA)

15:10-15:25 Unfolding the protein misfolding in chronic pancreatitis

Eszter Hegyi (Pécs, Hungary)

15:25-15:35 O-06: Creation of a GATA transcription factor binding site as underlying pathogenic mechanism of the common SPINK1 p.N34S pancreatitis risk haplotype

Lara Unger (Freising, Germany)

15:35-15:50 New kids on the block

Maren Ewers (Munich, Germany)

15:50-16:00 O-07: Characterisation of a new form of pancreatitis

Memoona Rajput Bhatti (Brussels, Belgium)

16:00-16:20 Coffee break

16:20-17:30 Cystic fibrosis

Chair: Michael Wilschanski (Jerusalem, Israel),
Grzegorz Oracz (Warsaw, Poland)

16:20-16:45 Impact of CFTR modulators on organ function

Frank Bodewes (Groningen, Netherlands)

Wednesday, June 28th 2023

- 16:45-17:10 **Diabetes and cystic fibrosis**
Andrea Párniczky (Pécs, Hungary)
- 17:10-17:20 **O-08: Acute pancreatitis is associated with gut dysbiosis in children**
Chinenye Dike (Birmingham, USA)
- 17:20-17:30 **O-09: Elevated pancreatic fluid and HCO₃⁻ secretion in diabetic mice is the result of increased CFTR function**
Viktória Venglovecz (Szeged, Hungary)
- 17:30-18:05 Peter Durie Memorial Lecture**
Chair: Isabelle Scheers (Brussels, Belgium),
Thomas Müller (Innsbruck, Austria)
- 17:30-17:40 **Peter Durie – life and work**
Michael Wilschanski (Jerusalem, Israel)
- 17:40-18:05 **Swachman-Diamond syndrome – molecular basis and disease spectrum**
Marco Cipolli (Verona, Italy)
- 18:05-18:55 Rare inherited diseases**
Chair: Isabelle Scheers (Brussels, Belgium),
Thomas Müller (Innsbruck, Austria)
- 18:05-18:30 **Molecular and clinical aspects of Johanson-Blizzard syndrome**
Martin Zenker (Magdeburg, Germany)
- 18:30-18:55 **Inborn errors of metabolism affecting the pancreas**
Johannes Häberle (Zurich, Switzerland)
- 19:00-21:00 Welcome reception with Tyrolean snacks** **CONGRESS CENTER**
Supported by the Agrarmarketing Tirol,
a member of the Lebensraum Tirol Holding

Program

Thursday, June 29th 2023

- 07:00-08:00 Pancreatology Editorial Board Meeting** VON HAYEK
- 07:00-08:00 YOUPPIE Breakfast** LIECHTENSTEIN
with the Mentor: Enrique de-Madaria (Alicante, Spain)
- 08:00-08:05 Welcome and Opening of the EPC**
Heiko Witt (Munich, Germany)
- 08:05-08:50 Chronic Pancreatitis**
Chair: María del Pilar Acedo Nuñez (London, UK),
William Greenhalf (Liverpool, UK)
- 08:05-08:20 Cathepsin B in pancreatitis: facts & fiction**
Andrea Geisz (Boston, USA)
- 08:20-08:30 O-10: DNGR-1 in dendritic cell limits pancreatic tissue damage during chronic pancreatitis via restraining IL-6-mediated Th17+ cell differentiation and persistent acinar-to-ductal metaplasia**
Li Wen (Beijing, China)
- 08:30-08:40 O-11: Pro-inflammatory cytokines of the IL-6 family induce regulatory T-cells and determine the severity of acute pancreatitis**
Juliane Glaubitz (Greifswald, Germany)
- 08:40-08:50 O-12: Orai1 calcium channel inhibition prevents progression of chronic pancreatitis**
Viktória Szabó (Szeged, Hungary)
- 08:50-10:10 Pancreatic cancer**
Chair: Takuji Okusaka (Tokyo, Japan), Andrew Hopper (Sheffield, UK)
- 08:50-09:05 Performing liquid biopsy for the management of pancreatic adenocarcinoma**
Stefania Bunduc (Bucharest, Romania)
- 09:05-09:15 O-13: Do infective complications of pancreatoduodenectomy affect recurrence and long-term survival rates?**
Teresa Perra (Sassari, Italy)

Thursday, June 29th 2023

- 09:15-09:25 **O-14: Nerve-derived CXCL8 promotes perineural invasion and associates with poor survival in pancreatic cancer**
Carmen Mota Reyes (Munich, Germany)
- 09:25-09:40 **Technical challenges for the surgeon after neoadjuvant therapy**
Ekin Demir (Munich, Germany)
- 09:40-09:50 **O-15: Ideal outcome after pancreatoduodenectomy: a transatlantic evaluation of a harmonised composite outcome measure**
Simone Augustinus (Amsterdam, Netherlands)
- 09:50-10:00 **O-16: Artificial intelligence-based quantification of residual cancer burden to evaluate the impact of neoadjuvant therapy in resected pancreatic cancer in the PREOPANC randomized trial**
Boris Janssen (Amsterdam, Netherlands)
- 10:00-10:10 **O-17: Predicting response for each component of the FOLFIRINOX regimen in pancreatic cancer patients**
Nelson Dusetti (Marseilles, France)
- 10:10-10:25 Coffee break**
- 10:25-12:30 Autoimmune pancreatitis (JPS-EPC)**
Chair: Kazushige Uchida (Kochi, Japan), Caroline Sophie Verbeke (Oslo, Norway)
- 10:25-10:50 **Roles of plasmacytoid dendritic cells in the development of AIP**
Kosuke Minaga (Osaka, Japan)
- 10:50-11:15 **Evidence-based therapy of AIP and the PrescrAIP perspective**
Peter Mačinga (Prague, Czech Republic)
- 11:15-11:40 **Efficacy and limitations of the biopsy-based diagnosis of type 1 and type 2 AIP**
Kenji Notohara (Okayama, Japan)
- 11:40-12:05 **Paediatric aspects of AIP**
Isabelle Scheers (Brussels, Belgium)
- 12:05-12:30 **Long-term prognosis and clinical course of AIP: a multi-center study in Japan**
Tetsuya Takikawa (Sendai, Japan)

Program

Thursday, June 29th 2023

12:30-14:30 Lunch & Poster Walk

12:30-14:30 Global guidelines on the management and treatment of pancreatic cystic neoplasms **VON HAYEK**

Chair: Marco del Chiaro (Denver, USA),
Marc Besselink (Amsterdam, Netherlands)

12:45-13:45 Satellite Symposium (see page 62)

14:30-15:20 Awards Session

Chair: Gabriele Capurso (Milan, Italy), Vinciane Rebours (Paris, France)

14:30-14:40 2023 Youppie Award – Glutamine sensing in pancreatic cancer: from mechanism of action to therapeutic perspective
Miriam Martini (Turin, Italy)

14:40-14:50 2023 Youppie Award – Pancreatic cancer and its variants: from histology and genomics to the clinic
Claudio Luchini (Verona, Italy)

14:50-15:00 Laudation for the 2022 EPC Lifetime Achievement Award
Jonas Rosendahl (Halle, Germany)

15:00-15:20 2022 EPC Lifetime Achievement Award Lecture: Consequences of chronic pancreatitis and exocrine pancreatic insufficiency
Natalya Gubergits (Odesa, Ukraine)

15:20-16:00 Endoscopy

Chair: Hana Algül (Munich, Germany), Antonios Vezakis (Athens, Greece)

15:20-15:30 O-18: Efficacy and safety of remimazolam versus propofol during endoscopic ultrasound: a multicentre randomised controlled study (an interim analysis)

Dong Hee Koh (Hwaseong-si, South Korea)

15:30-15:50 Endoscopic treatment of post pancreatitis fluid collections

Andrea Anderloni (Pavia, Italy)

15:50-16:00 O-19: Efficacy and safety of plastic, covered and uncovered self-expandable metal stents in the treatment of malignant biliary obstructions

Chiara Coluccio (Forli, Italy)

16:00-16:20 Coffee break

16:20-16:50 Satellite Symposium (see page 64)

16:50-17:40 Pancreatic cancer

Chair: Djuna Cahen (Rotterdam, Netherlands),
Ivonne Regel (Munich, Germany)

16:50-17:05 CRISPR/Cas9 screening for the detection of exploitable vulnerabilities

Christian Pilarsky (Erlangen, Germany)

17:05-17:15 O-20: Re-shaping the pancreatic cancer tumour microenvironment: the metastasis suppressor NDRG1 inhibits pancreatic cancer exosome biogenesis, packaging and release

Zaklina Kovacevic (Sydney, Australia)

17:15-17:30 Targeted delivery approaches in pancreatic cancer

Ujjwal Mahajan (Munich, Germany)

17:30-17:40 O-21: Tunnelling nanotubes provide a route for mutant Kras spreading in pancreatic cancer

Zheng Wang (Xi'an, China)

Program

Thursday, June 29th 2023

17:40-18:30 Cystic pancreatic lesions

Chair: Silvia Carrara (Rozzano, Italy),
Martin Lovecek (Olomouc, Czech Republic)

17:40-18:00 Current management of mucinous cystic lesions of the pancreas

Marco Del Chiaro (Denver, USA)

18:00-18:10 O-22: Small cyst size and slow growth rate are soothing features in individuals with pancreatic cysts undergoing surveillance

Iris Levink (Rotterdam, Netherlands)

18:10-18:20 O-23: Surveillance for presumed BD-IPMN of the pancreas: stability, size, and age identify targets for discontinuation

Giovanni Marchegiani (Padova, Italy)

18:20-18:30 O-24: Predictive clinical and imaging features of high-grade dysplasia in mucinous cystic neoplasms of the pancreas

Lina Aguilera Muñoz (Clichy, France)

18:30-19:30 YOUPPIE & HPSG joint Reception

By invitation only

OTTO MOLDEN FOYER

19:30-22:30 Faculty Dinner

By invitation only

Save the Date

epc2024.eu



56th EPC meeting

Santiago de Compostela | SPAIN
JUNE 26th-29th | **2024**

Program

Friday, June 30th 2023

07:00-08:30 EPC Council Meeting

LIECHTENSTEIN

07:30-08:40 Acute & autoimmune pancreatitis

Chair: Rainer Heuchel (Stockholm, Sweden),
Péter Hegyi (Pécs & Budapest, Hungary)

07:30-07:50 Pain in acute pancreatitis: How to move the field forward
Asbjørn Drewes (Aalborg, Denmark)

07:50-08:00 O-25: Long-term outcome of immediate versus postponed intervention in patients with infected necrotizing pancreatitis
Noor J. Sissingh (Amsterdam, Netherlands)

08:00-08:20 Antibiotics in acute pancreatitis – still an issue for debate?
Goran Poropat (Rijeka, Croatia)

08:20-08:30 O-26: Sarcopenia is associated with pancreatic exocrine insufficiency on laboratory and CT imaging findings in patients with chronic pancreatitis
Ryotaro Matsumoto (Sendai, Japan)

08:30-08:40 O-27: Comparison of diagnostic rate for type 1 autoimmune pancreatitis between the Japanese clinical diagnostic criteria and the international clinical diagnostic criteria
Tsukasa Ikeura (Osaka, Japan)

08:40-09:10 Pancreatic cancer

Chair: Beatrice Mohelnikova-Duchonova (Olomouc, Czech Republic),
Jin Lee (Hwaseong, South Korea)

08:40-08:50 PCE award 2022: Evaluation of bacteria-induced chemoresistance in in vitro models of pancreatic cancer
Mjriam Capula (Pisa, Italy)

08:50-09:00 O-28: Defeating gemcitabine resistance in pancreatic tumours with antibody-based CDA degrader
Marie Sorbara (Toulouse, France)

09:00-09:10 O-29: Med12 promotes immune evasion by enhancing endogenous retro-elements silencing in pancreatic ductal adenocarcinoma
Jing Xue (Shanghai, China)

09:10-10:10 Pancreas 2000

Chair: Julia Mayerle (Munich, Germany),
Emma Martínez-Moneo (Barakaldo, Spain)

09:10-09:20 What is Pancreas 2000?

Güralp Ceyhan (Istanbul, Turkey)

09:20-09:30 How Pancreas 2000 influenced my academic career

Johanna Laukkarinen (Tampere, Finland)

09:30-09:40 Course 9: Endoscopic or surgical management of ampullary neoplasia – The ESAP study

Marcus Hollenbach (Leipzig, Germany)

09:40-09:50 Course 9: Formal oncological and parenchyma-sparing resections for small pancreatic neuroendocrine tumors

Antonio Pea (Verona, Italy)

09:50-10:00 Course 10: Clinical impact of management strategies for malignant gastric outlet obstruction

Giuseppe Vanella (Milan, Italy)

10:00-10:10 Course 10: The unknown registry: A European registry of idiopathic acute pancreatitis

Lucía Guilabert Sanz (Alicante, Spain)

10:10-10:25 Coffee break

10:25-12:30 Pancreatic cancer (JPS-EPC)

Chair: Helmut Friess (Munich, Germany), Sohei Satoi (Osaka, Japan)

10:25-10:50 Early detection of pancreatic cancer: current situation in Japan

Reiko Ashida (Wakayama, Japan)

10:50-11:15 Early detection in high-risk individuals

Kasper A. Overbeek (Rotterdam, Netherlands)

11:15-11:40 Oncological benefit and limitation of neoadjuvant therapy for pancreatic cancer

Shuichi Aoki (Sendai, Japan)

Program

Friday, June 30th 2023

- 11:40-12:05 **Advanced pancreas surgery: are there limits?**
Robert Grützmann (Erlangen, Germany)
- 12:05-12:30 **Optimized treatment strategy for pancreatic cancer: best timing, minimally invasive surgery, and conversion surgery**
Atsushi Oba (Tokyo, Japan)
- 12:30-14:30 Lunch & Poster Walk**
- 12:30-13:30 Satellite Symposium (see page 64)**
- 12:35-13:55 ESPAC breakout meeting EPC 2023 (see page 30)** **LIECHTENSTEIN**
Chair: John Neoptolemos (Heidelberg, Germany)
- 13:30-14:25 COST project workshop (see page 31)** **VON HAYEK**
Chair: Federico Canzian (Heidelberg, Germany), Daniele Campa (Pisa, Italy)
- 14:30-15:40 Awards Session**
Chair: Heiko Witt (Munich, Germany), Enrique Domínguez-Muñoz (Santiago de Compostela, Spain)
- 14:30-14:40 **Rudolf Ammann – life and work**
Markus Lerch (Munich, Germany)
- 14:40-14:50 **2023 Rudolf Ammann Award: CD25+FOXP3+ regulatory T cells control pancreatic fibrosis**
Juliane Glaubitz (Greifswald, Germany)
- 14:50-15:00 **O-30: Same-session double EUS-bypass versus surgical gastroenterostomy and hepaticojejunostomy: an international multicentre comparison (Best clinical science abstract)**
Giuseppe Vanella (Milan, Italy)
- 15:00-15:10 **O-31: Designing new targeted therapies against stress granules formation in Kras-dependent pancreatic cancer (Best basic science abstract)**
Patricia Santofimia-Castaño (Marseilles, France)

- 15:10-15:20** Laudation for the 2023 EPC Lifetime Achievement Award
Günter Klöppel (Munich, Germany)
- 15:20-15:40** 2023 EPC Lifetime Achievement Award Lecture:
Do whales have a pancreas?
NN
- 15:40-16:20** **Studies**
Chair: Stefano Crippa (Milan, Italy),
John Neoptolemos (Heidelberg, Germany)
- 15:40-16:00** **Clinical studies – Ongoing and still needed studies in pancreatology**
Marc Besselink (Amsterdam, Netherlands)
- 16:00-16:10** **O-32: Total pancreatectomy with islet autotransplantation as an alternative to high-risk pancreatojejunostomy after pancreaticoduodenectomy: a prospective randomised trial**
Francesca Aleotti (Milan, Italy)
- 16:10-16:20** **O-33: The effect of neoadjuvant chemoradiotherapy on the immune profile of pancreatic ductal adenocarcinoma: in-depth analysis of the PREO-PANC-1 randomised controlled trial**
Dana A. M. Mustafa (Rotterdam, Netherlands)
- 16:20-16:40** **Coffee break**
- 16:40-17:25** **Pancreatic cancer**
Chair: Robert Jaster (Rostock, Germany), Renata Talar-Wojnarowska (Łódź, Poland)
- 16:40-16:55** **Pancreatic Cancer Research Priorities in Europe: Report from the 2nd Multistakeholder Brainstorming meeting**
Núria Malats (Madrid, Spain)
- 16:55-17:05** **O-34: How a PI3K interactor drives PDAC chemoresistance and metastasis while paving the way for PI3K-targeted therapy**
Andrea Costamagna (Torino, Italy)

Program

Friday, June 30th 2023

- 17:05-17:15 **O-35: Development of a novel and safe NUPR1 inhibitor with efficient anticancer activity for pancreatic cancer treatment**
Xi Liu (Marseilles, France)
- 17:15-17:25 **O-45: EUS-guided detective flow imaging (DFI): a new advanced imaging technique for the differential diagnosis of solid pancreatic tumours**
Daniel de la Iglesia-Garcia (Santiago de Compostela, Spain)
- 16:30-17:30 UEG EPI Guidelines Meeting** **LIECHTENSTEIN**
- 17:30-19:00 EPC General Assembly**
- 19:30-23:30 EPC Evening** **HORNBDEN**

07:30-08:30 Acute Pancreatitis Interest Group

LIECHTENSTEIN

Chair: Enrique de Madaria (Alicante, Spain),
Georgios Papachristou (Columbus, USA)

08:30-09:50 Pancreatic cancer

Chair: Yoshifumi Takeyama (Osaka, Japan), Roberto Valente (Umeå, Sweden)

08:30-08:50 Precision medicine in PDAC: a morphomolecular approach
Irene Esposito (Dusseldorf, Germany)

08:50-09:00 O-37: The Italian Registry of Families At Risk of Pancreatic Cancer (IR-FARPC): Long-term results of a prospective, multicentre trial
Fabio Casciani (Verona, Italy)

09:00-09:10 O-38: The impact of transcriptional subtyping on pathological staging and therapy response of pancreatic cancer
Michael Günther (Munich, Germany)

09:10-09:30 Minimally invasive pancreatic surgery: is Da Vinci really a game changer?
Thilo Hackert (Hamburg, Germany)

09:30-09:40 O-39: Early versus late removal drainage in patients who underwent pancreatic resection: a comprehensive systematic review and meta-analysis using trial sequential analysis
Claudio Ricci (Bologna, Italy)

09:40-09:50 O-40: Pharmacotyping, response prediction and tumour evolution in pancreatic cancer organoids
Johann Gout (Ulm, Germany)

09:50-10:00 O-41: Surveillance for pancreatic cancer in high-risk individuals leads to improved outcomes: a propensity score matched analysis
Derk Klatte (Leiden, Netherlands)

Program

Saturday, July 1st 2023

10:00-10:50 Pancreatitis

Chair: Corinne Bousquet (Toulouse, France),
Albrecht Neeße (Hamburg, Germany)

10:00-10:20 Solved and unsolved questions in the medical treatment of acute pancreatitis

Enrique de-Madaria (Alicante, Spain)

10:20-10:30 O-42: Pancreatitis – Microbiome As Predictor of Severity (P-MAPS): a prospective international multicentre translational study

Christoph Ammer-Herrmenau (Göttingen, Germany)

10:30-10:50 Thrombotic complications in pancreatic diseases: current management

Łukasz Nawacki (Kielce, Poland)

10:50-11:10 Coffee break

11:10-12:30 Neuroendocrine & pancreatic cancer

Chair: Claudio Pasquali (Padua, Italy), Patrick Michl (Heidelberg, Germany)

11:10-11:30 RNA biology in neuroendocrine neoplasms: new translational opportunities

Justo P. Castaño (Cordoba, Spain)

11:30-11:40 O-43: Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumours (NF-PanNETs) – a survival analysis from a prospective observational study

Valentina Andreasi (Milan, Italy)

11:40-11:50 O-44: A basal-like pancreatic cancer molecular subtype can be identified on EUS-acquired tissue and is associated to current smoking, lower Ca19.9 expression and worse prognosis

Livia Archibugi (Milan, Italy)

11:50-12:10 Treatment of pancreatic neuroendocrine neoplasms, are we on the way to personalised medicine?

Sebastian Krug (Halle, Germany)

12:10-12:20 **O-36: Spatial transcriptomic analysis of sensory neurons in murine pancreatic cancer reveals a potential role for neuron-mediated immune suppression in the tumour microenvironment**
Carmen Mota Reyes (Munich, Germany)

12:20-12:30 **O-46: Homologous recombination-deficient pancreatic cancer coordinates cancer-associated fibroblast programming to support cancer aggressiveness and chemoresistance**
Johann Gout (Ulm, Germany)

12:30-13:20 Fatty pancreas & pancreatitis

Chair: Federico Canzian (Heidelberg, Germany),
Antanas Gulbinas (Kaunas, Lithuania)

12:30-12:50 **Fatty pancreas**
Miroslav Vujasinovic (Stockholm, Sweden)

12:50-13:00 **O-47: Metformin reduces the risk of hypoglycaemia, major cardiovascular events, and all-cause mortality in patients with postpancreatitis diabetes mellitus: a nationwide population-based cohort study**
Line Davidsen (Aalborg, Denmark)

13:00-13:10 **O-48: Sodium valproate causes pancreatic injury in vitro and in vivo via dysregulation of one carbon metabolism**
Wenhao Cai (Liverpool, United Kingdom)

13:10-13:20 **O-49: Urine proteomics profiling identify novel acute and chronic pancreatitis diagnostic biomarkers in children**
Venkata Akshintala (Baltimore, USA)

13:20-13:40 Closing session

13:20-13:30 **EPC farewell**
Heiko Witt (Munich, Germany)

13:30-13:40 **See you in Santiago de Compostela**
Enrique Domínguez-Muñoz (Santiago de Compostela, Spain)

13:35-14:15 Lunch

Satellite Meetings

Friday, June 30th 2023

12:35-13:55 **ESPAC breakout meeting EPC 2023**

LIECHTENSTEIN

Chair: John Neoptolemos (Heidelberg, Germany)

ESPAC trial overview

John Neoptolemos (Heidelberg, Germany)

ESPAC translational research programme overview

Peter Bailey (Lisbon, Portugal)

ESPAC signature overview

Roma Kurilov (Heidelberg, Germany)

ESPAC sample logistics

Teresa Peccerella (Heidelberg, Germany)

ESPAC and GCP working group

William Greenhalf (Liverpool, UK)

ESPAC METAPAC results [circulating biomarker working group]

Julia Mayerle (Munich, Germany)

ESPAC secondary screening for PDAC [circulating biomarker working group]

Eithne Costello (Liverpool, UK)

ESPAC therapy-induced evolution working group

Xu Zhou (Lisbon, Portugal)

ESPAC PDO working group

Maximilian Reichert (Munich, Germany)

Friday, June 30th 2023

- 13:30-14:25 COST project workshop** VON HAYEK
Chair: Federico Canzian (Heidelberg, Germany), Daniele Campa (Pisa, Italy)
- 13:30-13:45 Introduction to PANDoRA and COST TRANSPAN**
Federico Canzian (Heidelberg, Germany)
- 13:45-13:50 Peripheral and portal venous KRAS ctDNA detection in pancreatic cancer**
Christine Nitschke (Hamburg, Germany)
- 13:50-13:55 PSCA-rs2976395 and pancreatic cancer development**
Chiara Corradi (Pisa, Italy)
- 13:55-14:00 Physical activity and pancreatic cancer risk**
Riccardo Farinella (Pisa, Italy)
- 14:00-14:05 Uncommon genetic alterations and risk of pancreatic cancer**
Pelin Ünal (Heidelberg, Germany)
- 14:05-14:10 Exposome and genome interactions and pancreatic cancer**
Giulia Peduzzi (Pisa, Italy)
- 14:10-14:15 Risk factors for impaired nutritional status in pancreatic cancer patients**
Bettina Budai (Budapest, Hungary)
- 14:15-14:20 IGF-1 and IGFBP-2 levels in chronic pancreatitis and pancreatic cancer**
Barbara Włodarczyk (Łódź, Poland)
- 14:20-14:25 Exosome-mediated communication between pancreatic cancer and Schwann cells**
Didem Karakaş Zeybek (Istanbul, Turkey)

ueg

The EPC ESPGHAN Postgraduate Course „Inherited Diseases of the Exocrine Pancreas“ on June 28, 2023 was made possible by generous support from the UEG.

United European Gastroenterology (UEG) is Europe's home and umbrella for multidisciplinary gastroenterology and unites over 50,000 engaged professionals from national and specialist societies, individual digestive health experts, and related scientists from all fields and career stages.

Cell and Molecular Biology

- P-01-01** Irisin/FNDC5 time-dependently and acutely regulate pancreatic lipase
Avital Horwitz (Ariel, Guatemala)
- P-01-02** Irisin/FNDC5 regulate carbohydrate metabolism in the exocrine pancreas
Avital Horwitz (Ariel, Israel)
- P-01-03** Development of a human model system for investigating pancreatic ducts
Lóránd Kiss (Szeged, Hungary)
- P-01-04** The importance of spatial transcriptomics in translational research: identification of drug-gable targets in PDAC tissue samples.
Dana A. M. Mustafa (Rotterdam, Netherlands)
- P-01-05** Visualising pancreatic neural structures using Golgi-Cox staining method
Alper Dogruoz (Munich, Germany)
- P-01-06** Modelling PIEZO1-mediated pressure-induced pancreatitis by human organoids with artificially adjustable cell polarity
Aletta Kiss (Szeged, Hungary)
- P-01-07** Do mechanical forces induce a protumoural dialogue between the tumour and the adjacent healthy tissue?
Claire Lac (Toulouse, France)

Exocrine pancreatic insufficiency

- P-02-01** A multicentre prospective study of exocrine pancreatic insufficiency at 3 months after acute pancreatitis attack
Anna Phillips (Pittsburgh, USA)
- P-02-02** Perioperative management of pancreatic exocrine insufficiency - evidence-based proposal for a paradigm shift in pancreatic surgery
Louisa Stern (Hamburg, Germany)
- P-02-03** Lp-One Study: observational prospective study to assess the relationship between hepatic steatosis and pancreatic exocrine function
Matteo Marasco (Rome, Italy)
- P-02-04** A patient support program complementing hospital care to enhance patients' ownership of pancreatic exocrine insufficiency treatment in the Netherlands
Denise van Marion (Amstelveen, Netherlands)
- P-02-05** Correlation between endoscopic ultrasound features according to Rosemont criteria and exocrine pancreatic function in chronic pancreatitis
Caterina Stornello (Milan, Italy)
- P-02-06** Pancreatic exocrine insufficiency is a risk factor for kidney stones in patients with chronic pancreatitis
Miroslav Vujasinovic (Stockholm, Sweden)

Posters

P-02-07 Diagnostic accuracy of faecal elastase-1 test for the diagnosis of pancreatic exocrine insufficiency: a systematic review and meta-analysis

Daniel de la Iglesia-Garcia (Santiago de Compostela, Spain)

P-02-10 The association between the severity of pancreatic exocrine insufficiency and computed tomography-based morphological severity in patients with chronic pancreatitis

Min Kyu Jung (Daegu, Republic of Korea)

P-02-11 The positive nutritional and gastrointestinal effects of elexacaftor/tezacaftor/ivacaftor in the treatment of cystic fibrosis

Lumir Kunovsky (Brno, Czech Republic)

Genetics

P-03-01 Discovery of pancreas enhancers and their respective target genes with an activity-by-contact model

Andreas W. Schmidt (Halle (Saale), Germany)

P-03-02 Genetic association analysis of variants in CUZD1 with chronic pancreatitis

Anna Just (Greifswald, Germany)

P-03-03 CEL-HYB1 haplotypes confer varying risk for chronic pancreatitis

Gergő Berke (Pécs, Hungary)

P-03-04 Exposome and genome interactions and pancreatic ductal adenocarcinoma susceptibility in the UK Biobank

Giulia Peduzzi (Pisa, Italy)

P-03-05 Complement system genetic variability shapes pancreatic cancer risk

Alberto Langtry (Madrid, Spain)

P-03-06 Decitabine reactivates gene expression of silenced genes in PDAC preclinical models

Maria Urbanova (Bratislava, Slovakia)

P-03-07 The CEL gene in chronic pancreatitis: characterisation of a new humanised compound heterozygous Cel16R/HYB1 mouse model

Ranveig Seim Brekke (Bergen, Norway)

P-03-08 Early onset of abnormal glucose tolerance in patients with cystic fibrosis: a systematic review and meta-analysis

Adrienn F.Kéri (Budapest, Hungary)

P-03-09 Hereditary pancreatitis - report of 73 paediatric patients

Grzegorz Oracz (Warsaw, Poland)

P-03-10 Characteristics of BRCA2 families in a familial pancreatic cancer registry

Phillip Hopley (Liverpool, United Kingdom)

P-03-11 A comprehensive gene-based analysis of uncommon genetic polymorphisms and risk of pancreatic ductal adenocarcinoma

Pelin Ünal (Heidelberg, Germany)

P-03-12 Impact of genetically driven inflammation on early pancreatic carcinogenesis

Tanvi Vikrant Inamdar (Halle (Saale), Germany)

P-03-13 The role of TRPV6 variants in chronic pancreatitis in Hungary

Zsafia Gabriella Pesei (Szeged, Hungary)

P-03-14 Significance of chymotrypsinogen C (CTRC) mutations c.180C>T and c.493+51C>A in Hungarian patients with chronic pancreatitis

Regina Stefanovics (Szeged, Hungary)

Acute Pancreatitis (clinical)

P-04-01 Altered gut microbiota in the early stage of acute pancreatitis predicts the occurrence of acute respiratory distress syndrome

Ziying Han (Beijing, China)

P-04-02 Disease and death of Alexander the Great: pancreatic necrosis?

N.B. Gubergrits (Odesa, Ukraine)

P-04-03 Machine learning improves prediction of severity and outcomes of acute pancreatitis: a prospective multi-centre cohort study

Jianing Li (Beijing, China)

P-04-04 Prevalence of islet cell autoimmunity in paediatric patients in index cases of acute pancreatitis

Jonathan Tatum (Cincinnati, USA)

P-04-05 Acute pancreatitis increases the risk of gastrointestinal cancer in type 2 diabetic patients: a Korean nationwide cohort study

Jikon Ryu (Seoul, Republic of Korea)

P-04-06 Serum phosphate levels in acute alcoholic pancreatitis

María Lourdes Ruiz Rebollo (Valladolid, Spain)

P-04-10 Systematic review of volume and methodological quality of randomised trials in acute pancreatitis

Nejo Joseph (Auckland, New Zealand)

P-04-11 Discharge protocol in acute pancreatitis: an international survey and cohort analysis

Rita Nagy (Budapest, Hungary)

P-04-12 Development of pancreatic diseases during long-term follow-up of patients with acute pancreatitis in a prospective nationwide cohort

Fem de Rijk (Rotterdam, Netherlands)

P-04-13 Anaemia predicts organ failure and mortality in acute pancreatitis

María Lourdes Ruiz Rebollo (Valladolid, Spain)

P-04-14 Predictors of pain evolution in acute pancreatitis. Post-hoc analysis of WATERFALL clinical trial

Lucia Guilabert (Alicante, Spain)

Posters

- P-04-15** Early predictors for infected necrotizing pancreatitis: a systematic review and a meta-analysis
Dorottya Tarján (Budapest, Hungary)
- P-04-16** Age-based comparison of the late complications and lifestyle factors after acute pancreatitis
Máté Verbói (Pécs, Hungary)
- P-04-17** Sarcopenia in acute pancreatitis: a scoping systematic review
Matta Kuzman (Newcastle upon Tyne, United Kingdom)
- P-04-18** Post-discharge mortality in acute pancreatitis: A prospective international cohort analysis of 2613 patients
Dóra Czapári (Pécs, Hungary)
- P-04-19** The degree of obesity has a serious effect on the outcome of acute pancreatitis and the development of other comorbidities: analysis of an international prospective cohort of 2244 cases
Andrea Szentesi (Pécs, Hungary)
- P-04-20** Comparing gut microbiota results of patients with one attack of acute pancreatitis and with chronic pancreatitis
Alexandra Mikó (Pécs, Hungary)
- P-04-21** The risk factors of acute pancreatitis progression into recurrent acute pancreatitis and chronic pancreatitis
Endre Botond Gagyi (Budapest, Hungary)
- P-04-22** Acute pancreatitis and the risk of dementia in diabetes: a nationwide cohort study
Woo Hyun Paik (Seoul, Republic of Korea)
- P-04-24** Pancreatic necrosis infection as a determinant of multiple organ failure and mortality in patients with acute pancreatitis using a step-up approach and the concept of enhanced recovery after surgery
Igor A. Kryvoruchko (Kharkiv, Ukraine)
- P-04-25** Bacteriology of infection complications in acute pancreatitis
Igor A. Kryvoruchko (Kharkiv, Ukraine)
- P-04-26** Biliary sludge, microlithiasis and gallstone-induced acute pancreatitis are associated with comparable clinical outcome: a single-centre analysis and narrative review of the literature
Simon Sirtl (Munich, Germany)
- P-04-27** Role of unknown significance (VUS) and non-disease-causing (NDC) CFTR gene mutations in the pathogenesis of acute pancreatitis
Federico Caldart (Verona, Italy)
- P-04-28** Risk of acute alcohol pancreatitis is not increased in patients with previous biliary pancreatitis in a long-term follow-up
Anssi Nikkola (Tampere, Finland)
- P-04-29** Effect of serum vitamin D levels on the severity of acute pancreatitis: a prospective study
Serkan Ocal (Antalya, Turkey)

P-04-31 Acute pancreatitis: leave no stone unturned

Maria Terrin (Rozzano (Milan), Italy)

P-04-32 Social deprivation increases the risk of acute pancreatitis but does not impact on disease severity and mortality

Francis Robertson (Newcastle, United Kingdom)

P-04-33 Lactated Ringer's solution reduces severity, mortality, systemic and local complications in acute pancreatitis: systematic review and meta-analysis

Klementina Ocskay (Budapest, Hungary)

P-04-34 Pancreatitis bundles: useful tools for acute pancreatitis

Toshihiko Mayumi (Nagoya, Japan)

P-04-35 Splenoportal veins thrombosis in severe acute pancreatitis: should we anticoagulate?

Alex Bausela Sainz (Barakaldo, Bizkaia, Spain)

P-04-36 Cost analysis of moderately-severe and severe acute pancreatitis

Alex Bausela Sainz (Barakaldo, Bizkaia, Spain)

P-04-37 Ineffectual process concerning the initiation of enteral tube feeding in acute pancreatitis. a prospective, international, multicentre cohort analysis of 1088 cases.

Inez Bosnyák (Pécs, Hungary)

P-04-38 Metabolic-associated fatty liver disease is associated with more severe acute pancreatitis: a prospective cohort analysis of 2053 cases

Szilárd Vánicsa (Pécs, Hungary)

P-04-39 COVID-19 and acute pancreatitis: not increased risk but reduced care

Marco Ferronato (Bologna, Italy)

P-04-40 Chronic liver diseases is an important risk factor in acute pancreatitis: systematic review and meta-analysis

Jakub Hoferica (Budapest, Hungary)

P-04-41 Time dependency and risk factors of splanchnic vein thrombosis development in the early phase of acute pancreatitis: a systematic review and meta-analysis

Ruben Zsolt Borbély (Budapest, Hungary)

P-04-42 Risk factors for diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis

Olga Julia Zahariev (Budapest, Hungary)

P-04-43 SARS-CoV-2 infection of the pancreas is dependent on host factor PLAC8

Lesly Ibarguén-González (Palma de Mallorca, Spain)

P-04-44 Can serum gasdermin D level predict severity of acute pancreatitis?

Guleycan Parca (Antalya, Turkey)

P-04-45 The role of magnesium in acute pancreatitis & pancreatic injury: a systematic review

Ilaria Pergolini (Munich, Germany)

Posters

P-04-46 Visceral arterial pseudoaneurysms in acute necrotizing pancreatitis - a single-centre retrospective study

Oleksii Dronov (Kyiv, Ukraine)

P-04-47 The impact of a multidisciplinary team evaluation on the diagnosis and management of acute and chronic pancreatitis in a tertiary referral centre

Gaetano Lauri (Milan, Italy)

P-04-48 External pancreatic fistula as a risk factor for erosive complications in patients with infected walled-off necrosis

Olexii Dronov (Kyiv, Ukraine)

P-04-49 Admission risk factors and predictors of moderate or severe paediatric acute pancreatitis: a systematic review and meta-analysis

Márk Félix Juhász (Budapest, Hungary)

P-04-50 Drug associated acute pancreatitis: a systematic review of clinical and preclinical evidence

Wenhao Cai (Liverpool, United Kingdom)

P-04-51 Pancreatitis-induced duodenal wall enlargement and gallbladder perforation. A disguised association?

Stephanie Tasayco (Barcelona, Spain)

P-04-52 Impact of gut decontamination by rifaximin in patients with predicted severe acute pancreatitis: a pilot study

Shivam Kalia (Bhubaneshwar, India)

P-04-53 Bacterial infections during acute pancreatitis occur due to amphipathic liponecrosis

Vijay Singh (Scottsdale, USA)

Chronic Pancreatitis (clinical)

P-05-01 Extra-pancreatic manifestations in pancreatitis - an international survey report

Chinenye Dike (Birmingham, USA)

P-05-02 Clinical evaluation of dynamic interfacial tensiometry in patients with chronic pancreatitis (CP)

Natalya Gubergrits (Odesa, Ukraine)

P-05-03 Rate and rehabilitation options in patients with post-gastric resection chronic pancreatitis

Natalya Gubergrits (Odesa, Ukraine)

P-05-04 A clinical case of severe drug-induced pancreatic and hepatic steatosis

Natalya Gubergrits (Odesa, Ukraine)

P-05-05 Morphological and functional changes in the small intestinal mucosa in chronic pancreatitis

N.V. Byelyayeva (Odesa, Ukraine)

- P-05-06** Glycaemic control and influencing factors among patients with post-chronic pancreatitis diabetes mellitus
Jun Ye (Shanghai, China)
- P-05-07** The Indian translation of the comprehensive pain assessment tool short form for chronic pancreatitis (COMPAT-SF)
Louise Kuhlmann (Aalborg, Denmark)
- P-05-08** One episode of acute pancreatitis is just the beginning: the incidence of recurrent acute and chronic pancreatitis: a systematic review and meta-analysis
Endre - Botond Gagyí (Budapest, Hungary)
- P-05-09** Age aspect of the immune status of patients with chronic pancreatitis
Nataliia Shevchenko (Odessa, Ukraine)
- P-05-10** Evaluation of disease recurrence and evolution into chronic pancreatitis in 492 patients after a first episode of acute pancreatitis
Salvatore Crucillà (Verona, Italy)
- P-05-11** Differences in experimental pain sensitivity between African American and non-African American individuals
Mahya Faghghi (Baltimore, USA)
- P-05-13** Psychological interventions improve mental health in inflammatory digestive system diseases: a systematic review and meta-analysis
Brigitta Teutsch (Budapest, Hungary)
- P-05-15** Impact of acute pancreatitis on progression to chronic pancreatitis: results from the PaN-Eus registry
Daniel Oyon (Galdakao, Spain)
- P-05-16** Overweight and obesity are frequent in patients with chronic pancreatitis. Results from de Basque-Navarrese registry of patients with chronic pancreatitis
Federico Bolado (Pamplona, Spain)
- P-05-17** Spinal excitability in patients with painful chronic pancreatitis
Cecilie Siggaard Knoph (Aalborg, Denmark)
- P-05-18** Chronic pancreatitis patients often have undiagnosed osteoporosis and sarcopenia
Mikael Parhiala (Tampere, Finland)
- P-05-19** The impact of pancreatic fibrosis at fibronectin and hyaluronic acid plasma levels: preliminary study results
Igor Khatkov (Moscow, Russian Federation)
- P-05-21** Paraduodenal pancreatitis: preliminary data from an Italian multicentre registry
Luca Barresi (Palermo, Italy)
- P-05-22** Surgery in chronic pancreatitis after implementation of multidisciplinary team assessment - a single centre prospective study from Oslo
Olof Vinge-Holmquist (Trondheim, Norway)

Posters

Autoimmune Pancreatitis

P-06-01 Autoimmune pancreatitis and micronutrients: a pioneer study

Miroslav Vujasinovic (Stockholm, Sweden)

P-06-02 Incidence of autoimmune pancreatitis detected after pancreatic resection performed for suspected malignancy: a scoping review

Zain A. Karamya (Szeged, Hungary)

P-06-03 Clinical outcomes of patients with type 2 autoimmune pancreatitis in a large single-centre cohort with long-term follow-up

Michele Carlin (Verona, Italy)

P-06-04 A positive cytokine/chemokine feedback loop establishes plasmacytoid dendritic cell-driven autoimmune pancreatitis in IgG4-related disease

Akane Hara (Osaka-Sayama, Osaka, Japan)

P-06-05 AiPPEAR: a multicentre study on AutoImmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR

Sara Nikolic (Maribor, Slovenia)

P-06-06 Validation of MRI-morphologic radiological diagnostic criteria in a retrospective cohort of autoimmune pancreatitis (AIP) patients

Elisabetta Goni (Munich, Germany)

Acute & Chronic Pancreatitis (experimental)

P-07-01 Natural compound library screening identifies corynoline for the treatment of pancreatic fibrosis and chronic pancreatitis

Pengyuan Wang (Shanghai, China)

P-07-02 Development of new molecules with potential pharmacological activity for the treatment of acute pancreatitis based on an esteric coupling reactions between trehalose (disaccharide) and non-steroidal anti-inflammatory drugs

Dalit Giladi (Haifa, Israel)

P-07-03 Loss of the intracellular transport protein CLN8 increases autophagy and ER-phagy in acute experimental pancreatitis

Lukas Zierke (Greifswald, Germany)

P-07-04 Sensors of apoptotic cells receptor tyrosine kinases AXL and MERTK modulate pancreatic tissue repair and remodelling

Bin Li (Shanghai, China)

P-07-06 Tenascin C deficiency impairs epithelial regeneration after caerulein-induced acute pancreatitis

Aslihan Yavas (Duesseldorf, Germany)

P-07-07 The anti-coagulant dabigatran inhibits trypsin and has therapeutic activity in trypsin-dependent pancreatitis

Zsofia Gabriella Pesei (Los Angeles, USA)

P-07-08 Inflammatory epigenetic priming of pancreatic acinar cells promotes tissue regeneration after renewed inflammation

Quan Zhou (Munich, Germany)

P-07-09 Protective effects of the insulin-mimetic, SPROTONE, on cellular models of acute pancreatitis

Rinta Mathew (Manchester, United Kingdom)

P-07-10 Genetic and functional analysis of chymotrypsin-like protease (CTRL) in chronic pancreatitis

Katharina Eiseler (Freising, Germany)

P-07-11 Depletion of α -SMA+ myofibroblast aggravates pancreatitis in mice

Prince Allawadhi (Munich, Germany)

P-07-12 Dimethyl trisulphide alleviates the severity of experimental acute pancreatitis through acinar cytoprotection

Erik Márk Orján (Szeged, Hungary)

P-07-13 Determining the role of Serpin E1/PAI-1 in the development and progression of chronic pancreatitis

Tünde Molnár (Szeged, Hungary)

P-07-14 The pancreatic proteases as new analgesic targets in acute and chronic pancreatitis

David Jungwirth (Munich, Germany)

P-07-15 Anti-inflammatory effects of Xuebijing injection on acute pancreatitis: network pharmacology identification and experimental validation

Linbo Yao (Chengdu, China)

P-07-16 Targeting N-methyl-D-aspartate (NMDA) receptor 1A reduces pain in chronic pancreatitis mouse models

Nedim Can Cevik (Istanbul, Turkey)

P-07-17 The microbiome in pancreatic disease: a technical audit

Jessica Hale (Liverpool, United Kingdom)

P-07-18 Transcriptomic profiling reveals molecular and inflammatory gene signatures of acute pancreatitis in cyclophilin D knockout and wild-type murine blood

D Wu (Liverpool, United Kingdom)

Endoscopy and imaging

P-08-02 Prognostic value of longitudinal body composition analysis using deep learning-based segmentation in pancreatic cancer

Sang Hyub Lee (Seoul, Republic of Korea)

P-08-03 Acute pancreatitis secondary to migration and impaction of the intragastric balloon

M. Angeles Luceño (León, Spain)

P-08-04 Exceptional annular pancreas divisum

Jesus Espinel (León, Spain)

Posters

P-08-05 A deep learning based approach to assess tumour characteristics in patients with pancreatic ductal adenocarcinoma

Dawid Rutkowski (Huddinge, Sweden)

P-08-06 CT radiomics analysis in the differential diagnosis between pancreatic cancer and chronic pancreatitis

Andrey Litvin (Denpasar, Indonesia)

P-08-07 Endoscopic papillary large balloon dilation with wide sphincterotomy and brief balloon expansion is safe and leads rarely in recurrence in large common bile duct stones

Antti Siiki (Tampere, Finland)

P-08-08 Morphology of the papilla can predict a higher rate of post-ERCP adverse events - a systematic review and meta-analysis

Edina Tari (Budapest, Hungary)

P-08-10 A machine-learning based decision tool selecting patients with idiopathic acute pancreatitis for endosonography to exclude a biliary aetiology

Simon Sirtl (Munich, Germany)

P-08-11 Influence of prevalence and localisation of necrotic lesions on the course of acute necrotizing pancreatitis

Igor Khomiak (Kyiv, Ukraine)

P-08-12 Endoscopic ultrasonography in the diagnosis and treatment of paraduodenal pancreatitis

Igor Khomiak (Kyiv, Ukraine)

P-08-13 Endosonography in the diagnosis and treatment of acute peripancreatic fluid collections

Igor Khomiak (Kyiv, Ukraine)

P-08-14 PROTOCOL trial – PROTon pump inhibitors and stent Occlusion rate Of Lumen apposing metal stents

Jacob Hamm (Göttingen, Germany)

P-08-15 EUS-guided gastroenterostomy versus enteral stenting for frailer patients with malignant gastric outlet obstruction: a matched prospective comparison

Giuseppe Vanella (Milan, Italy)

P-08-16 EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: a prospective series from the PROTECT registry

Giuseppe Vanella (Milan, Italy)

P-08-17 Same-session endoscopic diagnosis and symptoms' palliation in pancreatobiliary malignancies: clinical impact of rapid-on-site evaluation

Giuseppe Vanella (Milan, Italy)

P-08-18 Endoscopic ultrasound-guided detective flow imaging (DFI) to evaluate pancreatic microvascularisation in patients with non-calcific chronic pancreatitis: a prospective, single-centre, observational study

Julio Iglesias-Garcia (Santiago de Compostela, Spain)

- P-08-19** A long-term follow-up of patients with painless chronic pancreatitis after ESWL and endoscopic management
Xiaonan Xu (Shanghai, China)
- P-08-20** Impact of biliary stent on endoscopic ultrasound fine needle biopsy (EUS-FNB) performance in pancreatic solid lesions diagnosis
Serena Stigliano (Rome, Italy)
- P-08-21** Outcomes predictors in endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent: a systematic review with meta-analysis
Alessandro Fugazza (Rozzano, Italy)
- P-08-22** The impact of pancreatic fibrosis at multidetector computed tomography results: preliminary study results
Igor Khatkov (Moscow, Russian Federation)
- P-08-23** Shear wave elastography for the diagnosis of non-calcific chronic pancreatitis: a prospective, single-centre, observational study
Julio Iglesias-Garcia (Santiago de Compostela, Spain)
- P-08-24** Strain elastography for the diagnosis of non-calcific chronic pancreatitis (CP). Strain ratio or strain histogram?
Julio Iglesias-Garcia (Santiago de Compostela, Spain)
- P-08-25** Timing of lumen-apposing metal stents removal in pancreatic fluid collections: could we go beyond?
Gianmarco Marocchi (Rome, Italy)
- P-08-26** Deep learning-based algorithm for PDAC metastasis prediction on CT images
Nannan Xue (Madrid, Spain)
- P-08-27** Dynamic contrast-enhanced ultrasound (D-CEUS) to predict biological behaviour in pancreatic cancer: monocentric study preliminary results
Mattia Paratore (Rome, Italy)
- P-08-28** Clinical outcomes of endoscopic ultrasonography-guided transmural drainage with lumen apposing metal stent for peripancreatic fluid collection
Hiroki Yonemura (Sapporo, Japan)
- P-08-29** Pancreatic steatosis: metabolic implications and correlation with ultrasound findings
Sara Sofia De Lucia (Rome, Italy)
- P-08-30** Maintaining plastic stent after metal stent removal is associated with less recurrence of peripancreatic collections
Belen Agudo Castillo (Madrid, Spain)
- P-08-31** Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer
Giovanni Guarneri (Milan, Italy)

Posters

P-08-33 Endoscopic papillectomy: a multicentre, retrospective, nationwide study after the standardisation of the technique

Cecilia Binda (Forli-Cesena, Italy)

P-08-34 The use of a novel haemostatic peptide gel in the management of walled-off pancreatic necrosis (WOPN) drained using lumen apposing metal stents (LAMSs): a case series

Stefano Fabbri (Forli-Cesena, Italy)

P-08-35 Fully versus partially-covered self-expandable metal stents for palliation of distal malignant biliary obstruction: a meta-analysis.

Giuseppe Vanella (Milan, Italy)

P-08-36 Alternation of MRI and EUS in pancreatic cancer screening could increase detection of both pancreatic and extra-pancreatic findings

Ruggero Ponz de Leon Pisani (Milan, Italy)

P-08-37 Training in EUS: current state of training modalities from a worldwide survey

Livia Archibugi (Milan, Italy)

P-08-38 Endoscopic ultrasound-guided drainage of pancreatic fluid collections with two different dedicated metal stents: a nationwide, multicentre, propensity score-matched comparison

Chiara Coluccio (Forli, Italy)

P-08-39 Development and validation of the SDLD-score: a simplified tool to predict successful endoscopic papillectomy in ampullary lesions

Kien Vu Trung (Leipzig, Germany)

P-08-40 The clinical and procedure-related outcomes of endoscopic management of walled-off pancreatic necrosis

Dilara Turan Gökçe (Ankara, Turkey)

P-08-41 Safety of early versus late endoscopic or percutaneous interventions in infected necrotizing pancreatitis - a systematic review and meta-analysis

Cristina Patoni (Bucharest, Romania)

Pancreatic Surgery

P-09-07 Prediction of margin-free resection following neoadjuvant treatment for pancreatic ductal adenocarcinoma: a Bayesian model to predict R0 and R1 resection

Quoc Riccardo Bao (Padova, Italy)

P-09-08 The choice of the most appropriate suture threads for pancreatic anastomoses on the basis of their mechanical characteristics

Michele Pagnanelli (Milano, Italy)

P-09-09 Correlation between inflammation, vascularization, adipocyte percentage and exocrine cell percentage at the resection margin and the postoperative pancreatic fistula rate after distal pancreatectomy - a pilot study

Viola Palecek (Munich, Germany)

- P-09-11** Novel approach for locally advanced pancreatic cancer surgery: arterial resection and reconstruction first, RO-pancreatectomy and vein resection second. Experience of 107 arterial resections
Viacheslav Egorov (Moscow, Russian Federation)
- P-09-12** How surgeon can proceed when vein reconstruction in locally advanced pancreatic cancer seems impossible
Viacheslav Egorov (Moscow, Russian Federation)
- P-09-13** Pancreatic ductal hypertension is the main multifactor of developing severe diverse clinical manifestations in patients with chronic pancreatitis
Volodymir Klymenko (Zaporizhzhia, Ukraine)
- P-09-14** P-suPAR may reflect the inflammatory response after pancreatic surgery
Anu Aronen (Tampere, Finland)
- P-09-15** The devil is not as black as he is painted: establishing a pancreatic surgery programme
Viacheslav Kopetskyi (Kyiv, Ukraine)
- P-09-16** Personalised step-by-step surgical treatment of acute necrotizing pancreatitis with priority use of minimally invasive interventions
Igor Khomiak (Kyiv, Ukraine)
- P-09-18** Whole 16S rRNA sequencing of the oral microbiome predicts postoperative pancreatic fistula – a prospective observational cohort study
Christoph Ammer-Herrmenau (Goettingen, Germany)
- P-09-19** From the operating room to the biomedical engineering laboratory: preliminary results for the mechanical characterisation of the pancreatic tissue
Michele Pagnanelli (Milan, Italy)
- P-09-21** Influence of perioperative care factors on morbidity of pancreatoduodenectomy
Pavel Skalicky (Olomouc, Czech Republic)
- P-09-22** Liver cirrhosis increases mortality in patients undergoing pancreaticoduodenectomy: a systematic review and meta-analysis
Emmanouil Psaltis (Newcastle-upon-Tyne, United Kingdom)
- P-09-23** Laparoscopic vs. open distal pancreatectomy - a single centre experience
Carsten Jäger (Munich, Germany)
- P-09-25** A retrospective, multicentre, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients
Maximilian Kießler (Munich, Germany)
- P-09-26** Pathologic tumour response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?
Greta Donisi (Milan, Italy)
- P-09-27** Metastasectomy of isolated metachronous pulmonary oligometastases of PDAC prolongs OS and DFS in patients following radical pancreatectomy
Martin Lovecek (Olomouc, Czech Republic)

Posters

P-09-28 A modular perfusion circuit with predetermined physiological parameters for the development and understanding of whole organ ex vivo pancreas perfusion: insights from a porcine study
Zainab Rai (London, United Kingdom)

P-09-29 Minimally invasive versus open radical antegrade modular pancreateo-splenectomy for pancreatic ductal adenocarcinoma: an entropy balancing analysis in a multicentre study
Claudio Ricci (Bologna, Italy)

P-09-30 Borderline resectable and locally advanced pancreatic cancer: resectability and survival after neoadjuvant therapy
Simone Serafini (Padova, Italy)

P-09-32 The significance of lymph node dissection at the left side of superior mesenteric artery (SMA) during Whipple's procedure for pancreatic head cancer
Zipeng Lu (Nanjing, China)

P-09-33 Robotic distal pancreatectomy in a patient with a heterozygous pathogenic variant in the PALB2 Gene
Lucas Bárberi (Rio de Janeiro, Brazil)

P-09-34 Management of malignant gastric outlet obstruction (mGOO) due to pancreatic cancer in the era of EUS-gastroenterostomy: an international practice survey and case vignette study
Charles de Ponthaud (Paris, France)

P-09-35 International survey of anticoagulation following porto-mesenteric vessel resection/reconstruction in pancreatic surgery
Peter Szatmary (Liverpool, United Kingdom)

P-09-36 Performing robot-assisted pancreatoduodenectomy in octogenarian vs younger patients: a one-to-one case control study
Annalisa Comandatore (Pisa, Italy)

P-09-38 Health-related quality of life after laparoscopic versus open distal pancreatectomy according to PROMIS-29 profile
Nicolò Pecorelli (Milan, Italy)

P-09-39 Reappraisal of residual tumour status on pancreaticoduodenectomy margins: a single-institutional cohort of 858 patients with resected pancreatic head ductal adenocarcinoma following a standardised pathological protocol
Baobao Cai (Nanjing, China)

P-09-40 Surgical treatment of pancreatic neoplasia in children: a single-centre retrospective analysis of short-term outcomes
Veronika Rozhkova (Kyiv, Ukraine)

P-09-41 Intraoperative Gram staining of bile protocol to prevent infectious complications in pancreaticoduodenectomy
Luis Carlos Hinojosa Arco (Málaga, Spain)

P-09-42 Postoperative pancreatic fistula: is it possible to predict its appearance in the first two postoperative days?
Luis Carlos Hinojosa Arco (Málaga, Spain)

- P-09-44** Prevention and mitigation strategies for postoperative pancreatic fistula after pancreatoduodenectomy
Volodymyr Kopchak (Kyiv, Ukraine)
- P-09-45** Clinical significance of radical surgical treatment of patients with locally advanced tumours right anatomical segment of pancreas
Andrii Savytskyi (Kiev, Ukraine)
- P-09-46** Provincial prospective audit of pancreaticoduodenectomy in China: an analysis of 1172 Cases in the year of 2021
Kuirong Jiang (Nanjing, China)
- P-09-47** Inadequate lymph node examination leads to misclassification and affects survival in resected pancreatic ductal adenocarcinoma
Ruediger Goess (Munich, Germany)
- P-09-48** Failure-to-resection after surgical exploration for pancreatic cancer: predicting unnecessary surgery to optimize patient selection
Fabio Casciani (Verona, Italy)
- P-09-49** Comparison of total lymph node retrieval and survival with the standard Whipple procedure versus the pylorus preserving pancreatoduodenectomy in early pancreatic head tumours
Leonidas Chardalias (Athens, Greece)
- P-09-50** The interplay between preoperative anaemia, intraoperative blood loss and transfusions in pancreatoduodenectomy: a question unresolved
Fabio Casciani (Verona, Italy)
- P-09-51** Factors affecting prognosis after pancreatectomies for pancreatic cancer: a multivariate analysis
Konstantinos Iliakopoulos (Athens, Greece)
- P-09-52** Posterior-inferior approach retrograde spleen-preserving left pancreatectomy: how I do it
Yi Miao (Nanjing, China)
- P-09-53** Pancreatectomies in a tertiary hospital during the period 2012-2021: a retrospective study
Dimitris Politis (Athens, Greece)

Neuroendocrine Tumours

- P-10-01** Pancreatic neuroendocrine neoplasms in patients with more than 75 years of age: a single centre experience
Anna Caterina Milanetto (Padova, Italy)
- P-10-02** Outcome of pancreatic NETs with liver metastases surgically treated: a single centre experience
Anna Caterina Milanetto (Padova, Italy)
- P-10-03** Long-term health-related quality of life after surgery of pancreatic neuroendocrine neoplasms: a single centre experience of 32 years
Anna Caterina Milanetto (Padova, Italy)

Posters

P-10-04 Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumours (NF-PanNETs)

Anna Battistella (Milan, Italy)

P-10-05 The use of quantitative contrast-enhanced endoscopic ultrasound in the evaluation of pancreatic neuroendocrine tumours: can we move from quality to quantity? A proof-of-concept study

Matteo Tacelli (Milan, Italy)

P-10-06 Efficacy and safety of capecitabine and temozolomide (CAPTEM) in advanced gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN): a systematic review and meta-analysis

Matteo Tacelli (Milan, Italy)

P-10-07 Diagnostic work-up and surgical management of insulinoma - a retrospective analysis from a tertiary referral centre

Valentina Andreasi (Milan, Italy)

P-10-09 Mechanisms of CUX1-induced tumour progression in neuroendocrine tumours of the pancreas

Maryam khosravian (Halle (Saale), Germany)

P-10-10 Malignant insulinoma - single centre experience

David Hoskovec (Prague, Czech Republic)

P-10-11 Always look behind the rock: a case of an insulinoma hidden by a pancreatic stone

Marta Andreozzi (Rozzano, Italy)

P-10-12 The impact of metformin, insulin, and diabetes on the progression of pancreatic neuroendocrine tumours (PNETs)

Jonas Fredriksson (Umeå, Sweden)

P-10-13 Histology matters: incidence of major thrombotic events in pancreatic neuroendocrine tumours (PNETs) compared to pancreatic ductal adenocarcinomas (PDACs)

Olof Fransson (Umeå, Sweden)

Cystic pancreatic lesions

P-11-01 Accompanying cancer of other site may be a new prognosticator in patients with branch duct intraductal papillary mucinous neoplasm unfit for surgical treatment

Yeaji Jo (Seoul, Republic of Korea)

P-11-03 Preliminary clinical exome evaluation of intraductal papillary mucinous neoplasm patients by next generation sequencing

Fahimeh Jafarnezhad-Ansariha (Padua, Italy)

P-11-06 Serous cystadenocarcinoma of the pancreas: a review of the current literature

Michael Tolkacz (Royal Oak, USA)

P-11-07 The potential benefit of laparoscopy in distal pancreatectomy for cystic lesions in the enhanced recovery after surgery era: a multicentre propensity-score matched analysis

Giulia Gasparini (Milan, Italy)

- P-11-08** Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasms progression.
Manuel Gentiluomo (Pisa, Italy)
- P-11-09** Recurrence, recurrence patterns and management of recurrence after resection for invasive IPMN: data from 466 consecutive patients from a multicentre international cohort study
Francis Robertson (Newcastle, United Kingdom)
- P-11-10** Diagnostic challenges of pancreatic acinar cystic transformation: a single-centre retrospective study of 64 patients
Lina Aguilera Munoz (Clichy, France)
- P-11-11** Adjuvant chemotherapy does not impact on survival outcomes after resection for Invasive IPMN: data from 466 consecutive patients from an international multicentre cohort study
Francis Robertson (Newcastle, United Kingdom)
- P-11-12** IPMN progression over time: modifiable risk and protective factors
Tommaso Schepis (Rome, Italy)
- P-11-13** Impact of age, comorbidities and relevant changes on surveillance strategy of intraductal papillary mucinous neoplasms: a competing risk analysis
Giulio Belfiori (Milan, Italy)
- P-11-14** Contrast-enhanced endoscopic ultrasound in the differential diagnosis of pancreatic cystic lesions
Vincent Zoundjiekpon (Olomouc, Czech Republic)
- P-11-16** Role of endoscopic ultrasound to identify morphological features predictive of malignancy in patients undergoing surgical resection for presumed IPMN
Piera Zaccari (Milan, Italy)
- P-11-17** Recognition of GNAS and KRAS mutations in endoscopic ultrasound – fine needle aspiration (EUS-FNA) fluid samples from the main pancreatic duct (MPD) accurately discriminates intraductal papillary mucinous neoplasm (IPMN) from benign conditions with MPD dilatation
Guillem Soy (Barcelona, Spain)
- P-11-18** Progression of the branch duct intraductal papillary mucinous neoplasm: parametric time-to-event analysis, using frailty models and ancillary parameters of hazard curves
Claudio Ricci (Bologna, Italy)
- P-11-19** Diabetes mellitus and metabolic factors: “weighing” the risk of malignancy in IPMNs
Francesca Aleotti (Milano, Italy)
- P-11-20** The role of EUS in diagnosis and management of pancreatic cystic neoplasms: intention-to-treat analysis
Anna Burelli (Verona, Italy)
- P-11-21** Pancreatic cystic neoplasms: still high rates of preoperative misdiagnosis in the guidelines and EUS era
Roberto Salvia (Verona, Italy)
- P-11-22** Guiding the way: a comparative analysis of IPMN management in two European centres
Vladimir Djordjevic (Belgrade, Serbia)

Posters

Pancreatic Cancer (clinical)

P-12-01 Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer

Ayumi Kashiro (Tokyo, Japan)

P-12-02 Are serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 2 (IGFBP-2) levels useful in chronic pancreatitis (CP) and pancreatic adenocarcinoma (PDAC) differentiation?

Barbara Wlodarczyk (Lodz, Poland)

P-12-03 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analysed with common data model

Jun Kyu Lee (Goyang, Republic of Korea)

P-12-04 Pathologic complete response following preoperative chemotherapy vs. chemoradiotherapy in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis

Quoc Riccardo Bao (Padova, Italy)

P-12-05 Characteristic analyses of early-onset pancreatic cancer: a survey of international publications

Dong Luo (Changsha, China)

P-12-06 Peripheral and portal venous KRAS ctDNA detection as independent prognostic markers of early tumour recurrence in pancreatic ductal adenocarcinoma

Christine Nitschke (Hamburg, Germany)

P-12-07 Dermatological paraneoplastic syndrome in pancreatology: clinical case

Natalia Gubergits (Odesa, Ukraine)

P-12-08 Diagnostic accuracy of ki-67 labelling index in endoscopic ultrasonography-fine needle aspiration cytology and biopsy of pancreatic neuroendocrine neoplasms

Byoung Kwan Son (Uijeongbu, Republic of Korea)

P-12-09 Immunomodulatory effects and response prediction of FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma patients: implications for combination therapies

Casper W F van Eijck (Rotterdam, Netherlands)

P-12-10 Metabolite profiles in plasma distinguish between patients with periampullary cancer and benign pancreatic disease

Stina Margrethe Stålberg (Oslo, Norway)

P-12-11 Bile analysis in patients with bile duct obstruction

Jae Seon Kim (Seoul, Republic of Korea)

P-12-12 The added value of blood glucose monitoring in high-risk individuals undergoing pancreatic cancer surveillance

Aleksander Bogdanski (Leiden, Netherlands)

P-12-13 Impact of nationwide implementation of best practices in pancreatic cancer care (PACAP-1): a stepped-wedge cluster randomised controlled trial

Simone Augustinus (Amsterdam, Netherlands)

- P-12-14** Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system
Giulia Gasparini (Milan, Italy)
- P-12-15** Nutritional indices in an inpatient advanced pancreatic cancer treatment
Mariia Kiriukova (Moscow, Russian Federation)
- P-12-16** Add-on oxaliplatin after treatment failure of nanoliposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma – a retrospective study
Shih-Hung Yang (Taipei, Taiwan)
- P-12-17** The impact of different gemcitabine-based first-line regimens, gemcitabine plus nab-paclitaxel or S-1, on the efficacy of second-line liposomal irinotecan in patients with metastatic pancreatic cancer
Nai-Jung Chiang (Taipei, Taiwan)
- P-12-18** GATA6 expression modulates the immune phenotype in patients with (borderline) resectable pancreatic cancer
Casper WF van Eijck (Rotterdam, Netherlands)
- P-12-19** Risk factors for developing impaired nutritional status in pancreatic cancer patients: A systematic review and meta-analysis
Bettina Csilla Budai (Budapest, Hungary)
- P-12-20** Accuracy of endoscopic ultrasound-guided tissue sampling for the cyto-histological diagnosis of solid pancreatic tumours: analysis of a large prospective registry
Yessica Dominguez-Novoa (Santiago de Compostela, Spain)
- P-12-21** Pre-diagnostic phase of pancreatic cancer: what should we pay to attention?
Daniel Quiñones - Díaz (Barakaldo, Spain)
- P-12-22** Integration of metabolome and microbiome omics layers toward pancreatic cancer risk prediction
Francisco Jurado (Madrid, Spain)
- P-12-23** Artificial intelligence approaches to predict pancreatic ductal adenocarcinoma risk
Giulia Peduzzi (Pisa, Italy)
- P-12-24** Combined IL6R inhibition and immunotherapy as a novel neoadjuvant therapeutic approach in murine pancreatic cancer: a preclinical study protocol
Ibrahim Halil Gürcinar (Munich, Germany)
- P-12-25** Investigating possible relationships between pancreatic cancer and hypothyroidism
Ingrid Garajová (Parma, Italy)
- P-12-26** A profile of long-term pancreatic cancer survivors
Ingrid Garajová (Parma, Italy)
- P-12-27** Longitudinal changes in body composition and metabolic markers prior to diagnosis of pancreatic ductal adenocarcinoma
Derk Klatte (Jacksonville, USA)

Posters

P-12-28 Cigarette smoking impairs the response to mFOLFIRINOX in patients with pancreatic ductal adenocarcinoma

Pilar Lazzano (Milan, Italy)

P-12-29 Heterotaxy syndrome with agenesis of the dorsal pancreas: a dark twisted turn of events

Andreia Rei (Porto, Portugal)

P-12-30 Diagnostic delay at diagnosis and time-to-treatment in pancreatic cancer influence overall survival

Ruggero Ponz de Leon Pisani (Milan, Italy)

P-12-31 The prognostic impact of comprehensive histopathological disease assessment in resected pancreatic cancer

Michael Guenther (Munich, Germany)

P-12-33 Pancreatic enzyme replacement therapy influences survival in patients with incurable pancreatic cancer

Hanna Sternby (Lund, Sweden)

P-12-34 Fatty pancreas is a risk factor for pancreatic cancer: a systematic review and meta-analysis of 2956 patients

Mónika Lipp (Budapest, Hungary)

P-12-35 Chemotherapy regimens and survival in pancreatic cancer - a ten year single centre overview

Hanna Sternby (Lund, Sweden)

P-12-36 Endoscopic papillectomy for ampullary lesions in patients with familial adenomatous polyposis compared to sporadic lesions in a propensity-score matched cohort

Kien Vu Trung (Leipzig, Germany)

P-12-37 Unveiling the connection: a meta-analysis of environmental pollutants and pancreatic cancer

Luka Manic (Belgrade, Serbia)

P-12-38 Diagnostic adequacy of needles used in EUS-guided tissue acquisition of solid pancreatic masses - a systematic review and network meta-analysis

Marie Anne Engh (Budapest, Hungary)

P-12-39 Impact of endoscopic ultrasound-guided tissue acquisition on prognosis in resectable or borderline resectable pancreatic body and tail cancer

Tsukasa Ikeura (Osaka, Japan)

P-12-40 Safety of multimodality treatment with a combination of intra-operative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: The combi-CaRe study

Susanne Roth (Heidelberg, Germany)

Pancreatic Cancer (experimental)

- P-13-01** The anticancer effect of artesunate-induced ferroptosis and its role for overcoming oxaliplatin resistance in pancreatic cancer
Sang Hyub Lee (Seoul, Republic of Korea)
- P-13-02** Etoposide and navitoclax as triggers of senescence and senolysis: in vitro and in vivo studies in murine pancreatic cancer models
Denis Revskij (Rostock, Germany)
- P-13-03** In vivo CRISPR/Cas screening of immune checkpoint proteins in pancreatic cancer
Eva Lentsch (Erlangen, Germany)
- P-13-04** Interleukin-3 amplifies the development and progression of pancreatic ductal adenocarcinoma
Paul David (Erlangen, Germany)
- P-13-05** COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion
Bin Yan (Heidelberg, Germany)
- P-13-07** Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis
Simone Benitz (Detroit, USA)
- P-13-08** GARP expression in the local lymphatic microenvironment predicts the progression of pancreatic ductal adenocarcinoma
Sebastian Klöckner (Erlangen, Germany)
- P-13-09** Regulation of pancreatic cancer metastasis by signal conversion in the epigenome
Joana Aggrey-Fynn (Stuttgart, Germany)
- P-13-11** Proteomic analysis of co-cultured human pancreatic stellate cells and cancer cell-derived exosome cargo: novel insights into signalling pathways in pancreatic cancer
Chamini Perera (Sydney, Australia)
- P-13-12** Molecular mechanisms of perineural invasion in pancreatic cancer
Marta Pellegatta (Milan, Italy)
- P-13-13** Pancreatic proteases are mediators of pain in murine pancreatic cancer
Philli Gärtner (München, Germany)
- P-13-15** Glutamine deficiency in pancreatic tumours confers vulnerability to ferroptosis via H3K4 trimethylation
Xuqing Shen (Shanghai, China)
- P-13-16** Pancreatic cancer cells are addicted to expression of the PLAC8 mRNA, but not the encoded protein, for maintenance of genome integrity and cell viability
Maren Stark (Marburg, Germany)
- P-13-17** Sodium butyrate induces cell senescence in murine pancreatic intraepithelial neoplasia cells
Thanh Hoai Pham (Halle, Germany)

Posters

P-13-18 Immune disbalance in peripheral blood mononuclear cells of pancreatic ductal adenocarcinoma patients is related to low expression of AhR
Antanas Gulbinas (Kaunas, Lithuania)

P-13-19 Metabolic characterisation of pancreatic juice in pancreatic cancer: a novel prognostic tool?
Greta Donisi (Milan, Italy)

P-13-20 Prognostic significance of AXL and role of the associated pathways in modulating proliferation and migration in pancreatic ductal adenocarcinoma (PDAC)
Benoit Immordino (Pisa, Italy)

P-13-21 HFE H63D variant promotes epithelial to mesenchymal transition of pancreatic cancer in cell-cycle dependent manner
Federica Rubbino (Rozzano, Italy)

P-13-22 Impact of G9a and DNMT1 expression in pancreatic cancer survival: new potential epigenetic therapeutic strategy
Daniel Oyon (Galdakao, Spain)

P-13-23 Molecular characterisation of precursor lesions of pancreatic cancer and their microenvironment in KC and KPC mice
Leon Boshoven (Düsseldorf, Germany)

P-13-24 Expression of lysine demethylase 5a (Kdm5a) influences tumour aggressiveness in murine pancreatic cancer cells
Nicole Schreiner (Munich, Germany)

P-13-25 Feedback inhibition relationship between AHR and ELAVL1 in pancreatic cancer in vitro
Darius Stukas (Kaunas, Lithuania)

P-13-26 Pathological assessment of tertiary lymphoid structures in pancreatic cancer: development and validation of a novel haematoxylin-eosin based classification
Gwendolin Liptay (Munich, Germany)

P-13-27 Stratification of PDAC patients based on their tumoural multiomics prognostic profiles
Evangelina López de Maturana (Madrid, Spain)

P-13-28 The PSCA-rs2976395 functional variant is associated with pancreatic cancer development
Chiara Corradi (Pisa, Italy)

P-13-29 Expression of Irf3 and Irf7 in tumour cells drives pancreatic cancer development and progression
Lisa Fahr (Munich, Germany)

P-13-30 Physical activity and pancreatic cancer risk: a Mendelian randomization study
Riccardo Farinella (Pisa, Italy)

P-13-31 Biological role of acid sphingomyelinase for pancreatic carcinogenesis
Ahmed Alnatsha (Munich, Germany)

P-13-33 Results of the first investigation about the understanding and engagement at time of diagnosis of patients with pancreatic cancer: the Communi.CARE study
Monica Consolandi (Trento, Italy)

- P-13-34** An in ovo model to study tumour morphogenesis and metastatic dissemination of PDAC
Raphela Ranjan (Munich, Germany)
- P-13-35** Splicing regulation as a new potential prognostic tool for personalised medicine in PDAC
Veronica Ruta (Rome, Italy)
- P-13-36** Inverse correlation of abundance of sphingomyelins with length of associated N-acyl fatty acid chain contributes to pathogenesis of pancreatic cancer
Ujjwal M. Mahajan (Munich, Germany)
- P-13-37** Understanding the cellular mechanisms of cell death in pancreatic cancer models following irreversible electroporation and calcium combination therapy
Alexandra Tan (London, United Kingdom)
- P-13-38** Inflammatory landscape after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma
Riccardo Guastella (Padova, Italy)
- P-13-39** PLAC8 is associated with the classical subtype and regulates EMT in pancreatic ductal adenocarcinoma
Catalina M Perelló-Reus (Palma de Mallorca, Spain)
- P-13-40** Do surgical tumour resection and chemotherapy lead to liver inflammation and outgrowth of liver metastases? Insights from a clinically adapted pancreatic cancer mouse model
Leon Baumann (Kiel, Germany)
- P-13-41** The role of platelet-induced LGALS1 expression of pancreatic cancer cells in anoikis resistance
Alissa Ernesti (Halle (Saale), Germany)
- P-13-42** Examining the effects of cytidine deaminase in pancreatic ductal adenocarcinoma cell lines and relation to gemcitabine and capecitabine efficacy
William Rowley (Liverpool, United Kingdom)
- P-13-43** Pembrolizumab combined with IL6R-inhibition leads to tumour regression in murine pancreatic cancer
Okan Safak (Munich, Germany)
- P-13-44** Applying an automated image-based algorithm for phenotypical characterisation of cancer cell spheroids
Beate Gündel (Stockholm, Sweden)
- P-13-45** The role of CCN1 in the crosstalk between pancreatic stellate cells and Panc1 cancers cells in 3D spheroids
Beate Gündel (Stockholm, Sweden)
- P-13-46** Influence of cancer associated fibroblasts (CAFs) heterogeneity on shaping immunosuppressive tumour microenvironment in PDAC
Didem Saka (Munich, Germany)

Posters

- P-13-47** Small extracellular vesicles-mediated crosstalk between pancreatic cancer cells and neurons
Linhan Ye (Munich, Germany)
- P-13-48** Investigating the synergistic effects of irreversible electroporation and cisplatin on patient-derived pancreatic cancer models
Kristine Bunayog (London, United Kingdom)
- P-13-49** Metabolomics of duodenal juice for differentiating pancreatic cancer from benign disease
Kazuma Kishi (Sapporo, Japan)
- P-13-50** Location of tissue associated macrophages M2 in pancreatic cancer
Yasmina Amor Tijani (Heidelberg, Germany)
- P-13-51** Pancreatic cancer related diabetes: impaired glucose tolerance and insulin signalling may drive progression of pancreatic intraepithelial neoplasms (PanINs)
Rohit Sarkar (Sydney, Australia)
- P-13-52** The protective effect of atopic diseases against pancreatic cancer is not driven by Th2-biomarkers
Jiangchuan He (Madrid, Spain)
- P-13-53** Importance of MUC17 in the bile-induced pancreatic cancer progression
Eleonóra Gál (Szeged, Hungary)
- P-13-54** Role of myeloid cell population in pancreatic cancer progression and targeting of myeloid subpopulations
Atul Verma (Halle (Saale), Germany)
- P-13-55** Correlation analysis of the relationship between the level of apoptosis markers and the severity of liver failure
Olexii Dronov (Kyiv, Ukraine)
- P-13-56** Neural invasion in pancreatic cancer is characterised by beta-1-integrin- and N-cadherin-dependent heterotypic cell adhesion between pancreatic cancer cells and neural Schwann cells
Haoyu Quan (Munich, Germany)
- P-13-57** Phenotype screens of genetically engineered mouse models of pancreatic cancer identify a Tgfa-Ccl2-paxillin axis driving human-like perineural invasion
Rouzanna Istvánffy (Munich, Germany)
- P-13-58** The tumour biology of early onset pancreatic cancer – a matched case study
Muhammed Dervis Arslan (Munich, Germany)
- P-13-59** Indoleamine-2,3-dioxygenase as therapy target in pancreatic cancer
Aitana Guiseris Martinez (Munich, Germany)
- P-13-60** CD24 and EpCAM expression on endoscopic ultrasound fine needle biopsy pancreatic ductal adenocarcinoma samples
Bogdan Silviu Ungureanu (Craiova, Romania)

P-13-62 In-situ-characterisation of the tumour microbiome in pancreatic cancer

Sai Agash Surendran (Munich, Germany)

P-13-63 Neuropeptide Y silencing negatively impacts the invasion capacity of pancreatic cancer cells

Menar Ekizce (Istanbul, Turkey)

P-13-64 Precision therapy for pancreatic cancer; the role of patient derived cancer avatars

Daniel Hughes (Oxford, United Kingdom)

P-13-65 Innervation at acinar-to-ductal metaplasia stage of pancreatic cancer

Alper Dogruoz (Munich, Germany)

P-13-66 The roles of GalNT2 and St3Gal6 genes on neural invasion

Alper Dogruoz (Munich, Germany)

P-13-67 Exosome-mediated communication between pancreatic cancer cells and Schwann cells promotes aggressiveness of pancreatic cancer

Didem Karakas (Istanbul, Turkey)

P-13-68 K-Ras independence due to N-Ras expression in cancer cell lines giving resistance to K-Ras specific inhibitors

Robert Ferguson (New York, USA)

P-13-69 State-of-the-art tissue clearing and 3D imaging and its application in understanding neural invasion in pancreatic cancer

Ruediger Goess (Munich, Germany)

P-13-70 Simultaneous inhibition of GSK3 β and HDACs improves chemotherapeutic efficacy in pancreatic cancer cells and human pancreatic ductal adenocarcinoma organoids

Jingyu An (Heidelberg, Germany)

P-13-71 Target structure in pancreatic ductal adenocarcinoma: changes in heat shock protein 90

Aiste Gulla (Vilnius, Lithuania)

P-13-72 Profiling immuno-inflammatory and serum biomarkers for the early detection of pancreatic cancer

Pilar Acedo (London, United Kingdom)

P-13-73 The role of GSK3 β in DNA repair mechanisms and resistance in PDAC

Aiko J Bockelmann (Göttingen, Germany)

P-13-74 Multiplex analysis of pancreatic, oesophageal and rectal adenocarcinoma – a cross-cancer approach on the impact of neoadjuvant therapy on the tumour microenvironment

Leonard Richter (München, Germany)

P-13-75 High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance

Guangfu Wang (Nanjing, China)

P-13-76 Allelic regulation of Keratin 19 gene expression during pancreatic development and carcinogenesis

Jana Krüger (Ulm, Germany)

Posters

P-13-77 Loss of ATM facilitates nutrient stress-induced metabolic reprogramming supporting pancreatic cancer aggressiveness

Anna Härle (Ulm, Germany)

P-13-78 Protein expression mapping reveals molecular mechanisms in pancreatic cancer-related diabetes

Lucy Oldfield (Liverpool, United Kingdom)

Commercial Part of the meeting

We would like to thank the following companies for their support:

Platinum Sponsors



Gold Sponsors



Silver Sponsors



Bronze Sponsors



Symposia

Wednesday, June 28th 2023

12:15-13:15 **Satellite Symposium Sobi – Swedish Orphan Biovitrum AB** 

Familial Chylomicronaemia Syndrome (FCS) – a rare dyslipidaemia that causes acute pancreatitis

Chair: Klaus Parhofer (Munich, Germany)

Causes of pancreatitis and the role of triglycerides

Péter Hegyi (Pécs & Budapest, Hungary)

Severe hypertriglyceridaemia

Alberico Catapano (Milan, Italy)

FCS: treatment and clinical cases from diagnosis to treatment

Handrean Soran (Manchester, UK)

Close

Klaus Parhofer (Munich, Germany)

Thursday, June 29th 2023

12:45-13:45 **Satellite Symposium Nordmark Pharma GmbH**



Chair: Markus Lerch (Munich, Germany)

Gut functions, microorganisms, mechanisms and myths

Hannelore Daniel (Freising, Germany)

Familial Chylomicronaemia Syndrome (FCS) – a rare dyslipidaemia that causes acute pancreatitis

**EPC Annual Meeting 2023 (in cooperation with the JPS), Alpbach, Austria
Sobi™ Symposium, Wednesday 28 June 2023, 12:15–13:15 CEST**

We warmly invite you to join us for this symposium, where leading experts will explain the importance of identifying the underlying cause of pancreatitis, explore the causes and consequences of severe hypertriglyceridaemia and discuss clinical experiences of the diagnosis and treatment of Familial Chylomicronaemia Syndrome (FCS).

Agenda

Welcome
5-min

Klaus Parhofer (Chair)
Munich, Germany



Causes of pancreatitis and the role of triglycerides
12-min presentation, 5-min Q&A

Péter Hegyi
Budapest, Hungary



Severe hypertriglyceridaemia
12-min presentation, 5-min Q&A

Alberico Catapano
Milan, Italy



FCS: treatment and clinical cases from diagnosis to treatment
12-min presentation, 5-min Q&A

Handrean Soran
Manchester, UK



Close
4-min

Klaus Parhofer (Chair)
Munich, Germany



Symposia

Thursday, June 29th 2023

16:20-16:50 **Satellite Symposium Actim**

Chair: Sara Regnér (Lund, Sweden)



Actim

Post-operative acute pancreatitis: prevention and diagnosis
Johanna Laukkarinen (Tampere, Finland)

Friday, June 30th 2023

12:30-13:30 **Satellite Symposium Viatrix**



VIATRIS

New developments in Pancreatic Exocrine Insufficiency

Chair: J. Enrique Domínguez-Muñoz (Santiago de Compostela, Spain)

Pancreatin preparations are not all the same: Evidence from in vitro studies.

Jonas Rosendahl (Halle, Germany)

Diagnostic approach to PEI is not always the same: differences between chronic pancreatitis and pancreatic cancer.

Gabriele Capurso (Milan, Italy)

Therapeutic approach to PEI is not always the same: differences between chronic pancreatitis and pancreatic cancer.

J. Enrique Domínguez-Muñoz (Santiago de Compostela, Spain)



**Boston
Scientific**
Advancing science for life™



Every Patient. Multiple Solutions.

Transforming Endoscopy
in the **HPB*** space

➤ Visit our website
and discover
HPB solutions



* Hepato-pancreato-biliary

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at <http://www.IFU-BSCI.com> Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material is not intended for use in France.

ENDO-1613601-AA 2023 © Boston Scientific Corporation or its affiliates. All rights reserved.

General information

Meeting venue

Congress Centrum Alpbach

Alpbach 246, 6236 Alpbach

Phone: +43 5336 600 100

Mail: info@alpbach.at

All sessions take part in the conference hall "Herz-Kremenak" if not otherwise stated in the program.

Registration and conference

Registration desk opening hours:

Tuesday June 27 16:00–18:00

Wednesday June 28 08:00–18:30

Thursday June 29 07:00–18:30

Friday June 30 07:00–18:30

Saturday July 1 07:30–13:00

Name badge

Your name badge gives you admission to the scientific sessions, lunch and coffee breaks. Your badge must be worn at all times at the conference venue.

Coffee breaks

Coffee is served in the exhibition area.

Lunch

A buffet lunch is served Wednesday – Saturday in the exhibition area.

Internet access

There is free wi-fi available at the congress venue with the kind support of **Dr. Falk Pharma Österreich GmbH**



Network name is: **Alpbach**

No password is required.

Speaker's room

Please deliver your presentations in **Hall von Einem** no later than 90 minutes before your session starts. For morning speakers, please deliver the presentation in the afternoon before.

Local transportation

Alpbach is a small village and it's easy to get around. Restaurants, attractions and hotels are all located within walking distance from the congress venue.

Sightseeing

Please visit Alpbach Tourism's website: www.alpbachtal.at/en for more information on the varied tourist attractions and local sights of Alpbach.

Homepage - epc2023.eu

Our website will be continuously updated.

LUTATHERA®

Lutetium (¹⁷⁷Lu) oxodotretotide

WE COULDN'T
BELIEVE IT
EITHER

- LUTATHERA® provided a significant 79 % reduction in the risk of disease progression or death vs. control (NETTER-1)*.
- LUTATHERA® has a manageable safety profile with no new safety signals identified over a median follow-up of >6 years^{1,2}
- International guidelines recommend LUTATHERA® in midgut NET after progression on first-line SSAs^{3,4}
- Defined, 4-dose treatment regimen⁵

* Hazard Ratio 0.18 (95 % CI: 0.11 – 0.29)

1. Strosberg J et al. N Engl J Med 2017; 376: 125–135. 2. Strosberg J et al. Lancet Oncol 2021; 22: 1752–63. 3. Pavel M et al. Neuroendocrinology 2016; 103:172–185. 4. Pavel M et al. Ann Oncol. 2020; 31(7): 844–860. 5. Current LUTATHERA® Summary of Product Characteristics.

Lutathera® 370 MBq/ml Infusionslösung.

QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: 1 ml Lösung enthält am Tag und zum Zeitpunkt der Kalibrierung 370 MBq Lutetium (¹⁷⁷Lu)-Oxodotretotide. Die Gesamtmenge an Radioaktivität pro Einzeldosis-Durchstechflasche am Tag und zum Zeitpunkt der Infusion beträgt 7400 MBq. Das Volumen der Lösung in der Durchstechflasche wird aufgrund der volumetrisch fixierten Aktivität von 370 MBq/ml am Tag und zum Zeitpunkt der Kalibrierung auf ein Volumen zwischen 20,5 und 25,0 ml angepasst, um am Tag und zum Zeitpunkt der Infusion die benötigte Menge an Radioaktivität bereitzustellen. **Physische Eigenschaften** Lutetium-177 hat eine Halbwertszeit von 6,647 Tagen. Lutetium-177 zerfällt durch β -Strahlung zu stabilem Hafnium-177, wobei am häufigsten β - (79,3 %) mit einer Maximalenergie von 0,497 MeV emittiert wird. Die durchschnittliche Beta-Energie beträgt ungefähr 0,13 MeV. Es wird auch eine geringe Gamma-Energie emittiert, beispielsweise bei 113 keV (6,2 %) und 208 keV (11 %). **Sonstiger Bestandteil mit bekannter Wirkung:** Jeder ml Lösung enthält 0,14 mmol (3,2 mg) Natrium. **Sonstige Bestandteile:** Essigsäure, Natriumacetat, Gentisinsäure, Ascorbinsäure, Pentetsäure, Natriumchlorid, Natriumhydroxid, Wasser für Injektionszwecke **ANWENDUNGSGEBIETE:** Lutathera ist zur Behandlung von nicht resezierbaren oder metastatischen, progressiven, gut differenzierten (G1 und G2) Somatostatinrezeptor-positiven gastroenteropankreatischen neuroendokrinen Tumoren (GEP NETs) bei Erwachsenen indiziert. **GEGENANZEIGEN:** Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile. Bestehende oder vermutete Schwangerschaft oder wenn eine Schwangerschaft nicht ausgeschlossen werden kann (siehe Abschnitt 4.6). Nierenversagen mit einer Kreatinin-Clearance <30 ml/min. **PHARMAKOTHERAPEUTISCHE GRUPPE:** Therapeutische Radiotherapeutika, Verschiedene Radiotherapeutika, ATC-Code: V10XX04 **INHABER DER ZULASSUNG:** Advanced Accelerator Applications, 20 rue Diesel, 01630 Saint-Genis-Pouilly, Frankreich. Informationen betreffend Warnhinweise und Vorsichtsmaßnahmen für die Anwendung mit anderen Mitteln, Nebenwirkungen und Gewöhnungseffekte sind der veröffentlichten Fachinformation zu entnehmen. Ausführliche Informationen zu diesem Arzneimittel sind auf den Internetseiten der Europäischen Arzneimittel-Agentur <http://www.ema.europa.eu/> verfügbar. **Abgabe:** Rezeptpflichtig, wiederholte Abgabe verboten, Abgabe nur an Inhaber einer Bewilligung für den Umgang mit radioaktiven Stoffen gemäß Strahlenschutzgesetz. **Versions: 09/2022**

Novartis Pharma GmbH
Jakov-Lind-Straße 5, Top 3.05
1020 Wien

Tel. +43 1 866 57-0
www.novartis.at

 **NOVARTIS**


AT230/22363/48

Welcome reception with Tyrolean snacks

This event will take place Wednesday Wednesday, June 28th from 19:00 at the Conference Center Alpbach.

Dress code: Informal

At the reception you will be able to enjoy a light meal and beverages in the company of friends and colleagues.



EPC evening

The dinner will take place on Friday, June 30th at 19:30 at Restaurant Hornboden, located directly below the mountain station of the Wiedersbergerhorn cable car at 1827m above sea level.

Dress code: Smart casual

If you have registered for the EPC evening, you will receive your ticket (both for dinner and the cable car) along with your name badge upon registration.

Do not forget to bring your ticket for the cable car Wiedersbergerhornbahn Alpbach!

Departure from **Congress Centrum Alpbach (shuttle service)** starting from 19:00.

Last cable car will depart at 23:40.



TTFIELDS

TUMOR TREATING FIELDS THERAPY

**VISIT [TUMORTREATINGFIELDSTHERAPY.COM](https://www.tumortreatingfieldstherapy.com)
TO LEARN MORE ABOUT THE VERSATILITY
OF TTFIELDS THERAPY**



Only TTFields therapy harnesses the versatile power of electric fields to outsmart solid tumors and kill cancer cells

**IN YOUR FIGHT AGAINST CANCER,
MAKE YOUR NEXT MOVE ELECTRIC**





We are creating healthy futures.

As Platinum Sponsor to EPC 2023 Nordmark Pharma proudly presents:

Nordmark Satellite Symposium

Thursday, June 29th,
12.45 - 13.45

Chair: Prof. Markus Lerch
Prof. Hannelore Daniel:

**"Gut functions, microorganisms,
mechanisms and myths"**

Rudolf Ammann Prize 2023

As part of the award ceremony on
Thursday, June 29th, 14.30 - 15.30

Save the date:



Come to see us at our booth and enjoy a barista quality coffee!

Nordmark Pharma GmbH
Pinnauallee 4 | 25436 Uetersen | Germany
www.nordmark-pharma.de



Join us at the Viatrix Satellite Symposium EPC 2023



June 30, 2023



12:30 - 13:30 CET



© CCA, Freudenthaler Norbert

New developments in Pancreatic Exocrine Insufficiency (PEI)

— Speakers & Programme —

Therapeutic approach to PEI is not always the same: Differences between chronic pancreatitis and pancreatic cancer.



Chairman

Prof. J. Enrique Domínguez-Muñoz

Gastroenterologist, Head of Gastroenterology and Hepatology Department, University Hospital of Santiago de Compostela, Spain

Pancreatin preparations are not all the same: Evidence from in vitro studies.



Prof. Jonas Rosendahl (Halle, Germany)

Gastroenterologist, University Clinic Halle, Vice Chair in the Clinic for Internal Medicine I and W2-Professor for Translational Genomics of Pancreato-biliary diseases

Diagnostic approach to PEI is not always the same: Differences between chronic pancreatitis and pancreatic cancer.



Dr. Gabriele Capurso (Milan, Italy)

Gastroenterologist, Clinical Research Director, Pancreaticobiliary and EUS Unit Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milano, Italy